<!DOCTYPE html><html lang="en-GB"><head><meta charSet="utf-8"/><meta http-equiv="x-ua-compatible" content="ie=edge"/><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/><style data-href="/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css" id="gatsby-global-css">.page-header{margin:0 0 3rem}.page-header__pre-heading{font-size:1.125rem;line-height:1.5rem;display:block;margin:0}.page-header__heading{font-size:2.75rem;line-height:3.5rem;margin:0 0 .5rem}.page-header__lead{font-size:1.25rem;line-height:1.75rem;margin:0 0 .5rem}.page-header__cta{font-size:1rem;line-height:1.5rem;display:block;margin:0}@media print{.page-header__cta{display:none!important}}.breadcrumbs{font-size:1rem;line-height:1.5rem;list-style:none;margin:.5em 0 2em;max-width:100%;padding:0}@media print{.breadcrumbs{display:none!important}}.breadcrumbs__crumb{display:inline-block}.breadcrumbs__crumb:before{content:">";font-size:80%;margin:0 .25em}.breadcrumbs__crumb:first-child:before{display:none}.breadcrumbs a{color:#222;text-decoration:underline}.breadcrumbs a:hover{text-decoration:none}.breadcrumbs a:focus{color:#005ea5}.breadcrumbs a:active{color:#222}.OldIEMessage-module--container--2Z9pT{max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);margin:auto auto 1rem}.OldIEMessage-module--alert--3CB3M{background:#ffdfa4;border:1px solid #966f2f;margin:1rem auto 0;max-width:73.125rem;padding:1rem}.OldIEMessage-module--alert--3CB3M a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.OldIEMessage-module--alert--3CB3M a:visited{color:#4c2c92}.OldIEMessage-module--alert--3CB3M a:hover{color:#2e8aca}.OldIEMessage-module--alert--3CB3M a:focus{outline:.25rem solid #0092a6;color:#005ea5}.OldIEMessage-module--alert--3CB3M a:active{color:#222}.OldIEMessage-module--alert--3CB3M h2{margin-top:0}.OldIEMessage-module--alert--3CB3M h2,.OldIEMessage-module--alert--3CB3M p{max-width:600px}.OldIEMessage-module--lastP---CQws{margin-bottom:0}.CoronaMessage-module--wrapper--zRiaV{background:#ffeb3b;padding:.5rem 0}.CoronaMessage-module--wrapper--zRiaV p{margin-top:0}.CoronaMessage-module--wrapper--zRiaV a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.CoronaMessage-module--wrapper--zRiaV a:visited{color:#4c2c92}.CoronaMessage-module--wrapper--zRiaV a:hover{color:#2e8aca}.CoronaMessage-module--wrapper--zRiaV a:focus{outline:.25rem solid #0092a6;color:#005ea5}.CoronaMessage-module--wrapper--zRiaV a:active{color:#222}@media print{.CoronaMessage-module--wrapper--zRiaV{display:none}}.CoronaMessage-module--container--36Biz{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.CoronaMessage-module--container--36Biz>:last-child{margin-bottom:0}.SubNav-module--wrapper--yAXWY{background:#fff;color:#000;display:block}.SubNav-module--list--1K9bK{margin:0;padding:0}.SubNav-module--list--1K9bK li{list-style:none;margin:0}.SubNav-module--link--39i23{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222;display:block;font-weight:400;padding:.5rem 1rem .5rem 2rem;text-decoration:none}.SubNav-module--link--39i23:focus{color:#222;outline:.25rem solid #0092a6;outline-offset:-.5rem}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222}.SubNav-module--link--39i23:hover{background:#d6d6d6;color:#222;text-decoration:underline}.SubNav-module--imageLink--3xwIS{display:none}@media(min-width:56.25em){.SubNav-module--wrapper--yAXWY{border-bottom:.125rem solid #004650;bottom:0;height:3rem;left:0;position:absolute;width:100%}.SubNav-module--imageLink--3xwIS{display:inline-block}.SubNav-module--list--1K9bK{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);height:100%}.SubNav-module--list--1K9bK li{display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23{border:0;display:block;height:100%;padding:0 1rem}.SubNav-module--link--39i23[aria-current=page],.SubNav-module--link--39i23[aria-current=true]{background:transparent}.SubNav-module--link--39i23[aria-current=page]:after,.SubNav-module--link--39i23[aria-current=true]:after{display:none}.SubNav-module--link--39i23:before{content:"";display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border:0}}.SubNav-module--image--uq-a2{height:100%}.Nav-module--link--3JzDA .Nav-module--tooltip--1Uj-W{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Nav-module--link--3JzDA:focus-visible .Nav-module--tooltip--1Uj-W{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Nav-module--visuallyHidden--ORHqX{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Nav-module--wrapper--2_xng{display:none;position:relative}@media print{.Nav-module--wrapper--2_xng{display:none!important}}@media(min-width:56.25em){.Nav-module--wrapper--2_xng{display:block}}.Nav-module--wrapperExpanded--3RxQB{display:block}.Nav-module--nav--2aQpa abbr[title]{border-bottom:0;cursor:help;text-decoration:none}.Nav-module--myAccount--3lsif{border-top:1px solid #fff}@media(min-width:56.25em){.Nav-module--myAccount--3lsif{display:none}}.Nav-module--myAccountHeading--1A5_B{border:.25rem solid #004650;font-size:100%;margin:0;padding:.5rem 1rem}.Nav-module--menuWrapper--2fp8S{background:#004650;color:#fff;padding:.25rem 0}.Nav-module--menuList--264L-{list-style:none;margin:auto;padding:0}.Nav-module--menuList--264L->li{margin:0}a.Nav-module--link--3JzDA{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#fff;display:block;font-weight:400;padding:.5rem 1rem;text-decoration:none}a.Nav-module--link--3JzDA span{text-decoration:inherit}a.Nav-module--link--3JzDA:focus{color:#fff;outline:.25rem solid #fff;outline-offset:-.5rem;z-index:1}a.Nav-module--link--3JzDA:visited{color:#fff}a.Nav-module--link--3JzDA:active{background:#acadad;color:#222}a.Nav-module--link--3JzDA:hover{background:#d6d6d6;color:#222;text-decoration:underline}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{background:#fff;color:#222;font-weight:700}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-color:#0092a6;outline-offset:-.25rem}@media(min-width:56.25em){.Nav-module--wrapperWithSubLinks--3PUfX{padding-bottom:3rem}.Nav-module--menuList--264L-{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);display:-webkit-flex;display:flex;-webkit-flex-direction:row;flex-direction:row;-webkit-flex-wrap:nowrap;flex-wrap:nowrap;-webkit-justify-content:space-between;justify-content:space-between}.Nav-module--menuList--264L->li{-webkit-flex-grow:1;flex-grow:1}a.Nav-module--link--3JzDA{border-left-width:0;border-right-width:0;display:-webkit-flex;display:flex;-webkit-flex-direction:column;flex-direction:column;height:100%;-webkit-justify-content:center;justify-content:center;line-height:1.25;margin:0;padding:.5rem;position:relative;text-align:center}a.Nav-module--link--3JzDA:focus{outline-offset:-.25rem}a.Nav-module--link--3JzDA span{display:inline-block;vertical-align:middle;white-space:normal}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{margin:0 .25rem}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-offset:-.5rem}a.Nav-module--link--3JzDA[aria-current=page]:after,a.Nav-module--link--3JzDA[aria-current=true]:after{background:#fff;content:"";display:block;height:.25rem;left:0;position:absolute;top:100%;width:100%}a.Nav-module--link--3JzDA[aria-current=page]:hover:after,a.Nav-module--link--3JzDA[aria-current=true]:hover:after{background:#d6d6d6}}@media(min-width:56.25em)and (min-width:75em){a.Nav-module--link--3JzDA{padding:1rem}}.Autocomplete-module--ac--2PqiF .autocomplete__wrapper{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input{-webkit-appearance:none;border:1px solid #222;border-radius:0;box-sizing:border-box;margin-bottom:0;width:100%}.Autocomplete-module--ac--2PqiF .autocomplete__input{background-color:#e9e9e9!important;height:2.5rem!important;margin:0!important;max-width:100%!important;position:relative;z-index:101}.Autocomplete-module--ac--2PqiF .autocomplete__input:focus{outline:3px solid #0092a6;outline-offset:-3px;z-index:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-webkit-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-moz-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input:-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__hint{color:#bfc1c3;position:absolute}.Autocomplete-module--ac--2PqiF .autocomplete__input--default{padding:.5rem}.Autocomplete-module--ac--2PqiF .autocomplete__input--focused{outline:3px solid #0092a6;outline-offset:-3px}.Autocomplete-module--ac--2PqiF .autocomplete__input--show-all-values{padding:4px 34px 4px 4px;cursor:pointer}.Autocomplete-module--ac--2PqiF .autocomplete__dropdown-arrow-down{z-index:-1;display:inline-block;position:absolute;right:8px;width:24px;height:24px;top:10px}.Autocomplete-module--ac--2PqiF .autocomplete__menu{background-color:#fff;border:1px solid #d6d6d6;border-top:0;color:#34384b;margin:0;max-width:100%;padding:0;text-align:left;width:-webkit-calc(100vw - 2rem);width:calc(100vw - 2rem)}@media(min-width:37.5em){.Autocomplete-module--ac--2PqiF .autocomplete__menu{width:100%}}.Autocomplete-module--ac--2PqiF .autocomplete__menu--visible{display:block}.Autocomplete-module--ac--2PqiF .autocomplete__menu--hidden{display:none}.Autocomplete-module--ac--2PqiF .autocomplete__menu--overlay{box-shadow:0 .25rem 1rem .25rem rgba(0,0,0,.1);left:0;position:absolute;top:100%;z-index:100}.Autocomplete-module--ac--2PqiF .autocomplete__menu--inline{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option{border-left-width:0;border-bottom:1px solid #d6d6d6;border-right-width:0;border-top-width:1px;color:#005ea5;cursor:pointer;display:block;margin:0;position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option a{color:inherit;display:block;font-weight:400;padding:.5rem;text-decoration:none}.Autocomplete-module--ac--2PqiF .autocomplete__option mark{background:0;color:inherit;font-weight:700;padding:0}.Autocomplete-module--ac--2PqiF .autocomplete__option>*{pointer-events:none}.Autocomplete-module--ac--2PqiF .autocomplete__option:first-of-type{border-top-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option:last-of-type{border-bottom-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option--odd{background-color:#fafafa}.Autocomplete-module--ac--2PqiF .autocomplete__option--focused,.Autocomplete-module--ac--2PqiF .autocomplete__option:hover{background-color:#e9e9e9;color:#005ea5;outline:none;text-decoration:underline}.Autocomplete-module--ac--2PqiF .autocomplete__option--no-results{background-color:#fafafa;color:#646b6f;cursor:not-allowed}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input,.Autocomplete-module--ac--2PqiF .autocomplete__option{font-size:16px;line-height:1.25}.Search-module--search--2wNll{margin:0;padding-right:2.5rem;position:relative}.Search-module--label--1rrog{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute!important;width:1px}.Search-module--button--2FbnI{background:#393939;border:0;color:#fff;cursor:pointer;height:2.5rem;min-width:2.5rem;padding:0 .5rem;position:absolute;right:0;text-align:center;top:0;z-index:101}.Search-module--button--2FbnI:focus{outline:.25rem solid #0092a6}.Search-module--button--2FbnI .Search-module--icon--2JB42{font-size:150%;vertical-align:middle}.Account-module--account--1BtRh{position:relative}.Account-module--button--zZii1{background:#fff;border:1px solid #222;color:#222;cursor:pointer;display:inline-block;font-family:inherit;font-size:inherit;font-weight:400;height:2.5rem;line-height:2.5rem;padding:0 .5rem;text-decoration:none;vertical-align:middle;white-space:nowrap}.Account-module--button--zZii1:focus{outline:.25rem solid #0092a6}.Account-module--button--zZii1:visited{color:#222}.Account-module--button--zZii1:hover{border:1px solid #222}.Account-module--myAccount--3jTaq:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Account-module--myAccount--3jTaq[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Account-module--menu--3C46i{background:#fff;border:1px solid #393939;list-style:none;margin:.625rem 0 0;padding:0;position:absolute;right:0;top:100%;z-index:2}.Account-module--menu--3C46i:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i[aria-hidden=true]{display:none}.Account-module--menu--3C46i:before{border-bottom:.5rem solid #393939;border-left:.25rem solid transparent;border-right:.25rem solid transparent}.Account-module--menu--3C46i:after,.Account-module--menu--3C46i:before{bottom:100%;content:"";display:block;height:0;position:absolute;right:1rem;width:0}.Account-module--menu--3C46i:after{border-bottom:.4rem solid #fff;border-left:.2rem solid transparent;border-right:.2rem solid transparent;margin-right:1px}.Account-module--menu--3C46i li{border-top:1px solid #d6d6d6;list-style:none;margin:0}.Account-module--menu--3C46i a{color:#005ea5;display:block;padding:.5rem 1rem;text-decoration:none;white-space:nowrap}.Account-module--menu--3C46i a:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i a:hover{background:#e9e9e9;text-decoration:underline}.Header-module--header--3os44{background:#fff;border-bottom:.125rem solid #004650;box-sizing:border-box;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif}.Header-module--header--3os44 *,.Header-module--header--3os44 :after,.Header-module--header--3os44 :before{box-sizing:inherit;font-family:inherit}@media print{.Header-module--header--3os44{border-bottom:none}}.Header-module--container--1mfIr{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0 0}.Header-module--container--1mfIr:after{clear:both;content:"";display:table}.Header-module--home--1TCPb{color:#000;display:inline-block;float:left;height:1.875rem;margin-bottom:1rem}@media print{.Header-module--home--1TCPb:after{content:none!important}}.Header-module--home--1TCPb:focus{outline:.25rem solid #0092a6}.Header-module--home--1TCPb:visited{color:#000}.Header-module--home--1TCPb .Header-module--icon--4LSt5{height:100%;width:auto}.Header-module--wrapper--2e13D{display:-webkit-flex;display:flex;-webkit-flex-grow:1;flex-grow:1;float:right;-webkit-justify-content:space-between;justify-content:space-between;margin-bottom:1rem;width:50%}@media print{.Header-module--wrapper--2e13D{display:none!important}}.Header-module--wrapper--2e13D:after{clear:both;content:"";display:table}.Header-module--search--2nfnz{-webkit-flex-grow:1;flex-grow:1;float:left;margin-right:1rem;min-width:66.6666666667%}.Header-module--mobileMenuBtn--1LgyL{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:1px solid #222;float:right;font-family:inherit;font-size:110%;height:2.5rem;min-width:4.6875rem;white-space:nowrap}.Header-module--mobileMenuBtn--1LgyL:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Header-module--mobileMenuBtn--1LgyL[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Header-module--account--y72Q4{display:none}@media(max-width:56.24em){.Header-module--home--1TCPb{float:none}.Header-module--wrapper--2e13D{float:none;width:auto}}@media(min-width:56.25em){.Header-module--header--3os44{border-bottom:.25rem solid #fff}.Header-module--container--1mfIr{display:-webkit-flex;display:flex;-webkit-justify-content:space-between;justify-content:space-between}.Header-module--home--1TCPb{height:2.5rem;margin-right:2rem}.Header-module--wrapper--2e13D{-webkit-justify-content:flex-end;justify-content:flex-end}.Header-module--search--2nfnz{margin-right:2rem}.Header-module--mobileMenuBtn--1LgyL{display:none}.Header-module--account--y72Q4{display:block}}.SkipLinks-module--list--1WwLa{list-style:none;margin:0;padding:0}@media print{.SkipLinks-module--list--1WwLa{display:none!important}}.SkipLinks-module--list--1WwLa li{list-style:none;margin:0}.SkipLinks-module--link--hkZw8{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.SkipLinks-module--link--hkZw8:focus{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;left:.25rem;outline:3px solid #0092a6;overflow:visible;padding:.5rem 1rem;position:absolute;top:.25rem;white-space:nowrap;width:auto;z-index:1}.Social-module--wrapper--2nKsd{clear:left}.Social-module--list--E5R5J{list-style:none;margin:0;max-width:100%;padding:0}.Social-module--list--E5R5J li{margin:0 0 .25rem}.Social-module--list--E5R5J svg{margin:-.125rem .25rem 0 0;vertical-align:middle}@media(min-width:37.5em){.Social-module--list--E5R5J li{float:left;margin:0 1rem 0 0}}@media(min-width:56.25em){.Social-module--wrapper--2nKsd{clear:none}.Social-module--wrapper--2nKsd li{float:none;margin:0 0 .25rem}}.Legal-module--wrapper--3AYMO{font-size:.875rem;line-height:1.25rem;background:#393939;padding:1rem 0}.Legal-module--wrapper--3AYMO a{text-decoration:underline}.Legal-module--container--3TTBh{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.Legal-module--menu--1e1Iy{margin:0 0 1rem}@media print{.Legal-module--menu--1e1Iy{display:none!important}}.Legal-module--menu--1e1Iy ul{list-style:none;margin:0;max-width:100%;padding:0}.Legal-module--menu--1e1Iy li{margin:0}.Legal-module--menu--1e1Iy a{display:block}.Legal-module--copyright--34nsI{font-size:.875rem;line-height:1.25rem;margin:0}@media print{.Legal-module--copyright--34nsI{float:none!important;max-width:100%}}@media(min-width:37.5em){.Legal-module--menu--1e1Iy li{display:inline-block;margin-right:1rem}}@media(min-width:75em){.Legal-module--wrapper--3AYMO:after,.Legal-module--wrapper--3AYMO:before{content:" ";display:table}.Legal-module--wrapper--3AYMO:after{clear:both}.Legal-module--menu--1e1Iy{float:left;margin:0}.Legal-module--copyright--34nsI{float:right}}.Services-module--link--2y_1q .Services-module--tooltip--pg3nW{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Services-module--link--2y_1q:focus-visible .Services-module--tooltip--pg3nW{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Services-module--visuallyHidden--t9mfm{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Services-module--wrapper--2qOoE{margin:0 0 2rem}.Services-module--list--3SZQu{list-style:none;margin:0;padding:0}.Services-module--list--3SZQu li{margin:0 0 .25rem}@media(min-width:37.5em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;width:33.3333333333%}}@media(min-width:56.25em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;margin:0;width:25%}}.Pages-module--wrapper--30REl{margin:0 0 2rem}.Pages-module--list--vvSk4{list-style:none;margin:0;padding:0}.Pages-module--list--vvSk4 li{margin:0 0 .25rem}@media(min-width:25em){.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}@media(min-width:37.5em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 0 0 2rem;width:66.6666666667%}}@media(min-width:56.25em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 2rem;width:50%}.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}.Footer-module--link--CGIYk .Footer-module--tooltip--1zoJv{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Footer-module--link--CGIYk:focus-visible .Footer-module--tooltip--1zoJv{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Footer-module--visuallyHidden--3CCnP{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Footer-module--footer--2QrGZ{background:#222;box-sizing:border-box;color:#fff;contain-intrinsic-size:350px;content-visibility:auto;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;margin:2rem 0 0}.Footer-module--footer--2QrGZ a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.Footer-module--footer--2QrGZ a:visited{color:#fff}.Footer-module--footer--2QrGZ a:hover{color:#d6d6d6}.Footer-module--footer--2QrGZ a:focus{outline:.25rem solid #fff;color:#fff}.Footer-module--footer--2QrGZ a:active{color:#d6d6d6}.Footer-module--footer--2QrGZ *,.Footer-module--footer--2QrGZ :after,.Footer-module--footer--2QrGZ :before{box-sizing:inherit}.Footer-module--footer--2QrGZ a{font-weight:400}.Footer-module--container--1iuoB{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0}.Footer-module--container--1iuoB:after,.Footer-module--container--1iuoB:before{content:" ";display:table}.Footer-module--container--1iuoB:after{clear:both}@media print{.Footer-module--container--1iuoB{display:none!important}}.Footer-module--logo--3DGKv{display:block;height:0;margin:0 0 2rem;padding:0 0 29.0496453901px;position:relative;width:80px}.Footer-module--logo--3DGKv svg{display:block;height:100%!important;left:0;position:absolute;top:0;width:100%!important}@media(min-width:56.25em){.Footer-module--logo--3DGKv{margin-bottom:1rem}}.BackToTop-module--wrapper--2Z0EU{margin-top:3rem}@media print{.BackToTop-module--wrapper--2Z0EU{display:none}}.BackToTop-module--nav--1DPZ6{background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}.BackToTop-module--anchor--1Nia6{display:block;line-height:1rem;padding:1rem 0}.BackToTop-module--anchor--1Nia6:visited{color:#005ea5}.BackToTop-module--anchor--1Nia6 svg{-webkit-transition:all .25s ease;transition:all .25s ease}.BackToTop-module--anchor--1Nia6:hover{background:#f4f4f4}.BackToTop-module--anchor--1Nia6:hover svg{-webkit-transform:translateY(-.125rem);transform:translateY(-.125rem)}@supports((position:-webkit-sticky) or (position:sticky)){.BackToTop-module--wrapper--2Z0EU{bottom:0;left:0;margin:0;pointer-events:none;position:absolute;right:0;top:min(100vh,-webkit-calc(100% - 3rem));top:min(100vh,calc(100% - 3rem));width:100%;z-index:99}.BackToTop-module--nav--1DPZ6{position:-webkit-sticky;position:sticky;pointer-events:all;top:-webkit-calc(100vh - 3rem);top:calc(100vh - 3rem);background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-regular.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-regular.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:italic;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-italic.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-italic.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:700;src:local("Lato"),url(../../../../fonts/lato-v17-latin-700.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-700.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:900;src:local("Lato"),url(../../../../fonts/lato-v17-latin-900.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-900.woff) format("woff")}/*! normalize.css v8.0.1 | MIT License | github.com/necolas/normalize.css */html{line-height:1.15;-webkit-text-size-adjust:100%}body{margin:0}main{display:block}h1{font-size:2em;margin:.67em 0}hr{box-sizing:content-box;height:0;overflow:visible}pre{font-family:monospace,monospace;font-size:1em}a{background-color:transparent}abbr[title]{border-bottom:none;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}b,strong{font-weight:bolder}code,kbd,samp{font-family:monospace,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}img{border-style:none}button,input,optgroup,select,textarea{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}[type=button]:-moz-focusring,[type=reset]:-moz-focusring,[type=submit]:-moz-focusring,button:-moz-focusring{outline:1px dotted ButtonText}fieldset{padding:.35em .75em .625em}legend{box-sizing:border-box;color:inherit;display:table;max-width:100%;padding:0;white-space:normal}progress{vertical-align:baseline}textarea{overflow:auto}[type=checkbox],[type=radio]{box-sizing:border-box;padding:0}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}details{display:block}summary{display:list-item}[hidden],template{display:none}.show-print{display:none!important}@media print{.show-print{display:block!important}}@media print{.hide-print{display:none!important}}@media print{.remove-appended-print-link:after{content:none!important}}@media print{*{background:transparent!important;box-shadow:none!important;color:#000!important;text-shadow:none!important}a,a:visited{text-decoration:underline}}@media print{h1 a:after,h2 a:after,h3 a:after,h4 a:after,h5 a:after,h6 a:after{content:none!important}}@media print{a[href]:after{content:" (" attr(href) ")"}}@media print{abbr[title]:after{content:" (" attr(title) ")"}}@media print{.ir a:after,a[href^="#"]:after,a[href^="javascript:"]:after{content:""}}@media print{blockquote,pre{border:1px solid #999;page-break-inside:avoid}}@media print{thead{display:table-header-group}}@media print{img,tr{page-break-inside:avoid}}@media print{img{max-width:100%!important}}@media print{img:not([alt]),img[alt=""]{display:none!important}}@media print{@page{margin:.5cm}}@media print{h2,h3,p{orphans:3;widows:3}}@media print{h2,h3{page-break-after:avoid}}.clearfix:after,.clearfix:before{content:" ";display:table}.clearfix:after{clear:both}.container{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.container--full{max-width:100%;padding:0 2%;width:auto}html{box-sizing:border-box;font-size:.9375rem;overflow-x:hidden}html *,html :after,html :before{box-sizing:inherit}@media(min-width:56.25em){html{font-size:1.03125rem;font-size:-webkit-calc(.375rem + 1vw);font-size:calc(.375rem + 1vw)}}@media(min-width:75em){html{font-size:1.125rem}}body{background:#f4f4f4;color:#222;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;font-style:normal;line-height:1.5rem;overflow-x:hidden;text-rendering:optimizelegibility}img{max-width:100%}hr{background:0;border:0;border-top:.0625em solid #adadad;margin:2em 0;padding:0}.p,p{font-size:1rem;line-height:1.5rem;font-feature-settings:"kern","onum","liga"}.lead,.p,p{margin-bottom:1rem;margin-top:1rem;font-weight:400;max-width:66ch}.lead{font-size:1.25rem;line-height:1.75rem}code{background:#e9e9e9;border:1px solid #adadad;border-radius:.125em;color:#222;display:inline-block;font-family:Monaco,Menlo,Consolas,Courier New,monospace;margin:0 0 .125em;padding:0 .25em}pre code{background:transparent;border:0;margin:0}.mark,mark{background-color:#fff999;padding:0 .25em}.small,small{font-size:85%}.h6,h6{font-size:1rem}.h5,.h6,h5,h6{line-height:1.5rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h5,h5{font-size:1.125rem}.h4,h4{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h3,h3{font-size:1.75rem;line-height:2rem}.h2,.h3,h2,h3{margin-bottom:1rem;margin-top:2rem;clear:both;font-weight:700;max-width:66ch}.h2,h2{font-size:2.25rem;line-height:2.5rem}.h1,.h2+.h3,.h2+h3,h1,h2+.h3,h2+h3{margin-top:0}.h1,h1{font-size:2.75rem;line-height:3.5rem;margin-bottom:1rem;clear:both;font-weight:900;max-width:66ch}.h1+.h2,.h1+h2,h1+.h2,h1+h2{margin-top:0}a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}a:visited{color:#4c2c92}a:hover{color:#2e8aca}a:focus{outline:.25rem solid #0092a6;color:#005ea5}a:active{color:#222}.link--inverse{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.link--inverse:visited{color:#fff}.link--inverse:hover{color:#d6d6d6}.link--inverse:focus{outline:.25rem solid #fff;color:#fff}.link--inverse:active{color:#d6d6d6}.inverse-links a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.inverse-links a:visited{color:#fff}.inverse-links a:hover{color:#d6d6d6}.inverse-links a:focus{outline:.25rem solid #fff;color:#fff}.inverse-links a:active{color:#d6d6d6}.list,ol,ul{font-feature-settings:"kern","onum","liga";margin-left:1rem;max-width:66ch;padding:0}.list--unstyled{list-style:none;margin-left:0;max-width:none;padding:0}.list--loose .list__item,.list--loose li{margin-bottom:.25rem}.list--piped{list-style:none;margin-left:0;padding:0}.list--piped .list__item,.list--piped li{display:inline-block;margin-right:-.25rem}.list--piped .list__item a,.list--piped li a{padding:.5rem}.list--piped .list__item:after,.list--piped li:after{border-left:1px solid #004650;content:"\200B";display:inline-block;margin:0 .5em;overflow:hidden;text-indent:-99px;vertical-align:middle;width:0}.list--piped .list__item:first-child a,.list--piped li:first-child a{padding-left:0}.list--piped .list__item:last-child:after,.list--piped li:last-child:after{display:none}.quote{font-size:1.25rem;line-height:1.75rem;border-left:.25em solid #004650;font-weight:400;margin:2rem 0;padding:0 0 0 4rem;position:relative}.quote:before{color:#004650;content:"\201C";display:block;font-family:Arial,sans-serif;font-size:5rem;font-weight:700;left:0;line-height:.8;position:absolute;text-align:center;top:0;width:4rem}@media print{.quote:before{color:#000}}.quote p{font-size:inherit}.quote cite,.quote footer{font-size:1rem;line-height:1.5rem;font-style:normal}table{background:#fff;border:1px solid #adadad;border-collapse:collapse;display:block;margin:0 0 1rem;max-width:100%;overflow-y:hidden;overflow-x:auto;width:100%!important}table th{vertical-align:bottom}table td{vertical-align:top}table td,table th{border:1px solid #adadad;padding:.5rem;text-align:left}table td:first-child,table th:first-child{border-left:0}table td:last-child,table th:last-child{border-right:0}table td p,table th p{margin-top:0}table :not(thead)+tbody tr:first-child th,table tbody tr:first-child th,table thead tr:first-child th{border-top:0}table tbody tr:last-child td{border-bottom:0}table tbody tr:nth-child(2n)>td{background-color:#e9e9e9}html{overflow-x:visible;scroll-behavior:smooth}@media(prefers-reduced-motion){html{scroll-behavior:auto}}body{font-family:Lato,Trebuchet MS,Roboto,Helvetica Neue,Helvetica,Arial,sans-serif;position:relative}.visually-hidden{position:absolute;overflow:hidden;clip:rect(0 0 0 0);height:1px;width:1px;margin:-1px;padding:0;border:0}#content-start:focus{outline:none}footer{margin-top:0!important}@supports((position:-webkit-sticky) or (position:sticky)){.Layout-module--main--1OIFf{position:relative;padding-bottom:4rem}}.stacked-nav{background:#fff;border:1px solid #adadad;margin:0 0 2em}@media print{.stacked-nav{display:none!important}}.stacked-nav__root{font-size:1rem;line-height:1.5rem;border-bottom:1px solid #adadad;font-weight:700;margin:0;max-width:none;position:relative;text-decoration:none}.stacked-nav__root a{color:#222}.stacked-nav__root--no-link{padding:.5em}.stacked-nav__hint{color:#222;display:block}.stacked-nav__hint :active{color:#fff}.stacked-nav__list{list-style:none;margin:0;max-width:100%;padding:0}.stacked-nav__list-item{border-top:1px solid #adadad}.stacked-nav__content-wrapper{display:block}.stacked-nav a{color:#005ea5;display:block;padding:.5em;position:relative;text-decoration:none}.stacked-nav a[aria-current=page],.stacked-nav a[aria-current=true]{background:#e9e9e9;font-weight:700}.stacked-nav a[aria-current=page]:before,.stacked-nav a[aria-current=true]:before{background:#004650;content:"";display:block;height:100%;left:0;position:absolute;top:0;width:.25em}.stacked-nav a:hover{background:#d6d6d6}.stacked-nav a:active{background:#004650;color:#fff}.stacked-nav a:active span{color:#fff}.stacked-nav__nested{list-style:none;margin:0;padding:0}.stacked-nav__nested .stacked-nav__content-wrapper{padding-left:1rem!important}.stacked-nav__nested ul .stacked-nav__content-wrapper{padding-left:2rem!important}.TopicChaptersMenu-module--toggleButton--2MGXA{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:#e9e9e9;border:1px solid #adadad;color:#005ea5;cursor:pointer;display:block;margin:0 0 2rem;padding:1rem 2rem 1rem .5rem;position:relative;text-align:left;width:100%}.TopicChaptersMenu-module--toggleButton--2MGXA:focus{outline:.25rem solid #0092a6;z-index:1}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=false]+.stacked-nav{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]{border-bottom:0;margin:0}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]+.stacked-nav{display:block}@media(min-width:37.5em){.TopicChaptersMenu-module--toggleButton--2MGXA{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded]+.stacked-nav{display:block}}.TopicChaptersMenu-module--icon--27uSj{color:#005ea5;right:.5rem;position:absolute;top:50%;-webkit-transform:translateY(-50%);transform:translateY(-50%)}.ChapterContents-module--wrapper--3ONbu{position:relative}.ChapterContents-module--printBtn--Rk_Zs{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;bottom:100%;cursor:pointer;display:none;padding:0}.ChapterContents-module--printBtn--Rk_Zs:visited{color:#4c2c92}.ChapterContents-module--printBtn--Rk_Zs:hover{color:#2e8aca}.ChapterContents-module--printBtn--Rk_Zs:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterContents-module--printBtn--Rk_Zs:active{color:#222}.ChapterContents-module--printBtn--Rk_Zs svg{font-size:1.25rem;line-height:1.75rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterContents-module--printBtn--Rk_Zs:hover svg{color:#2e8aca}@media(min-width:37.5em){.ChapterContents-module--wrapper--3ONbu:after,.ChapterContents-module--wrapper--3ONbu:before{content:" ";display:table}.ChapterContents-module--wrapper--3ONbu:after{clear:both}.ChapterContents-module--menu--3Epka{float:left;margin-right:1rem;width:-webkit-calc(25% - .5rem);width:calc(25% - .5rem)}.ChapterContents-module--landing--3klSq,.ChapterContents-module--onThisPage--1333P{float:right;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + .5rem);overflow:hidden;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}}@media(min-width:56.25em){.ChapterContents-module--printBtn--Rk_Zs{display:block;margin-bottom:3rem;position:absolute;right:0}.ChapterContents-module--menu--3Epka{margin-right:2rem;width:-webkit-calc(25% - 1rem);width:calc(25% - 1rem)}.ChapterContents-module--landing--3klSq{width:-webkit-calc(75% - 1rem);width:calc(75% - 1rem)}.ChapterContents-module--onThisPage--1333P{position:-webkit-sticky;position:sticky;top:0;width:-webkit-calc(16.66667% - 1rem);width:calc(16.66667% - 1rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + 1rem);width:-webkit-calc(58.33333% - 2rem);width:calc(58.33333% - 2rem)}}@media print{.ChapterContents-module--menu--3Epka,.ChapterContents-module--onThisPage--1333P,.ChapterContents-module--printBtn--Rk_Zs{display:none}.ChapterContents-module--body--1XBoo{width:100%}}.ChapterBody-module--wrapper--2HCfk>.visually-hidden:first-child+*>:first-child{margin-top:0}.ChapterBody-module--wrapper--2HCfk h2:focus,.ChapterBody-module--wrapper--2HCfk h3:focus,.ChapterBody-module--wrapper--2HCfk h4:focus,.ChapterBody-module--wrapper--2HCfk h5:focus,.ChapterBody-module--wrapper--2HCfk h6:focus{outline:0!important}.ChapterBody-module--basisWrapper--3JBM_{border:1px solid #adadad;margin-top:1rem;max-width:66ch}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-top:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK{padding:0 1rem 1rem}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK>:last-child{margin-bottom:0}.ChapterBody-module--headerWrapper--qSIFw{padding:1rem;position:relative}.ChapterBody-module--toggleBtn--3g0p7{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;cursor:pointer;display:block;margin-top:-.5rem;padding:0}.ChapterBody-module--toggleBtn--3g0p7:visited{color:#4c2c92}.ChapterBody-module--toggleBtn--3g0p7:hover{color:#2e8aca}.ChapterBody-module--toggleBtn--3g0p7:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterBody-module--toggleBtn--3g0p7:active{color:#222}.ChapterBody-module--toggleBtn--3g0p7:after{content:"";height:100%;left:0;position:absolute;top:0;width:100%}.ChapterBody-module--toggleBtn--3g0p7 svg{font-size:1.125rem;line-height:1.5rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterBody-module--toggleBtn--3g0p7:hover svg{color:#2e8aca}.ChapterBody-module--body--2n0CK[aria-hidden=true]{display:none}@media print{.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-bottom:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK[aria-hidden=true]{display:block}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--toggleBtn--3g0p7{display:none}}.ChapterOnThisPage-module--wrapper--2zc7n{margin-bottom:2rem}.ChapterOnThisPage-module--heading--2SdDN{margin-top:0}.ChapterOnThisPage-module--rootList--2II70{list-style:disc}.ChapterOnThisPage-module--subList--Pwxy9{list-style:circle}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:none}@media(min-width:56.25em){.ChapterOnThisPage-module--heading--2SdDN{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:0}@supports((position:-webkit-sticky) or (position:sticky)){.ChapterOnThisPage-module--rootList--2II70 a[aria-current=location]{font-weight:700}.ChapterOnThisPage-module--rootList--2II70 a:focus+.ChapterOnThisPage-module--subList--Pwxy9{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--subList--Pwxy9{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.ChapterOnThisPage-module--subList--Pwxy9:focus-within{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--expandedSubList--1m1WN{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:list-item}}}</style><link rel="sitemap" type="application/xml" href="../../../../sitemap.xml"/><title data-react-helmet="true">Scenario: Diarrhoea - antibiotic associated | Management | Diarrhoea - antibiotic associated | CKS | NICE</title><link data-react-helmet="true" rel="search" type="application/opensearchdescription+xml" href="../../../../opensearch.xml" title="CKS"/><link data-react-helmet="true" rel="icon" href="../../../../favicon.ico"/><link data-react-helmet="true" rel="canonical" href="index.html"/><meta data-react-helmet="true" name="description" content="Covers the management of antibiotic associated diarrhoea."/><meta data-react-helmet="true" property="og:description" content="Covers the management of antibiotic associated diarrhoea."/><meta data-react-helmet="true" property="og:url" content="https://cks.nice.org.uk/topics/diarrhoea-antibiotic-associated/management/diarrhoea-antibiotic-associated/"/><meta data-react-helmet="true" property="og:locale" content="en_GB"/><meta data-react-helmet="true" property="og:type" content="website"/><meta data-react-helmet="true" property="og:title" content="Scenario: Diarrhoea - antibiotic associated | Management | Diarrhoea - antibiotic associated | CKS | NICE"/><meta data-react-helmet="true" property="og:image" content="https://cks.nice.org.uk/open-graph-image.png"/><meta data-react-helmet="true" property="og:image:width" content="1200"/><meta data-react-helmet="true" property="og:image:height" content="630"/><meta data-react-helmet="true" name="twitter:card" content="summary"/><meta data-react-helmet="true" name="twitter:image" content="https://cks.nice.org.uk/twitter-summary-image.png"/><meta data-react-helmet="true" name="twitter:image:alt" content="NICE and CKS logos"/><meta data-react-helmet="true" name="twitter:site" content="@NICEcomms"/><meta data-react-helmet="true" name="twitter:creator" content="@NICEcomms"/><meta data-react-helmet="true" name="theme-color" content="#004650"/><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+'';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer', 'GTM-54QC4NL');</script><link rel="manifest" href="../../../../manifest.webmanifest" crossorigin="anonymous"/><meta name="theme-color" content="#004650"/><link rel="apple-touch-icon" sizes="48x48" href="../../../../icons/icon-48x48.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="72x72" href="../../../../icons/icon-72x72.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="96x96" href="../../../../icons/icon-96x96.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="144x144" href="../../../../icons/icon-144x144.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="192x192" href="../../../../icons/icon-192x192.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="256x256" href="../../../../icons/icon-256x256.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="384x384" href="../../../../icons/icon-384x384.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="512x512" href="../../../../icons/icon-512x512.png@v=28734348209eeeae5c03a37867f1beb1"/><link as="script" rel="preload" href="../../../../webpack-runtime-28c424ef71f39faedaf0.js"/><link as="script" rel="preload" href="../../../../framework-34da02e39e1f104d9937.js"/><link as="script" rel="preload" href="../../../../app-53a71c38b210970893c4.js"/><link as="script" rel="preload" href="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js"/><link as="script" rel="preload" href="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js"/><link as="script" rel="preload" href="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"/><link as="fetch" rel="preload" href="../../../../page-data/topics/diarrhoea-antibiotic-associated/management/diarrhoea-antibiotic-associated/page-data.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/sq/d/3666801979.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/app-data.json" crossorigin="anonymous"/><script src="https://cdn.nice.org.uk/cookie-banner/cookie-banner.min.js" type="text/javascript" async=""></script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54QC4NL" height="0" width="0" style="display: none; visibility: hidden" aria-hidden="true"></iframe></noscript><div id="___gatsby"><div style="outline:none" tabindex="-1" id="gatsby-focus-wrapper"><div><div class="Header-module--header--3os44"><header aria-label="Site header"><ul class="SkipLinks-module--list--1WwLa" aria-label="Accessibility links"><li><a href="index.html#content-start" class="SkipLinks-module--link--hkZw8">Skip to content</a></li><li><a href="https://www.nice.org.uk/accessibility" class="SkipLinks-module--link--hkZw8">Accessibility help</a></li></ul><div class="Header-module--container--1mfIr"><a href="https://www.nice.org.uk/" aria-label="Home" class="Header-module--home--1TCPb"><svg viewBox="0 0 4616 512" fill="none" class="Header-module--icon--4LSt5" aria-hidden="true" focusable="false"><path d="M1626 44v175h-22L1497 71v148h-19V44h22l107 147V44h19zm130 154a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-35 18-48 11-14 27-20 47-20 19 0 34 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm109 16V104h-27V87h27V40h19v47h30v17h-30v115h-19zm88-180v26h-21V39h21zm-20 48h20v132h-20V87zm107-2c20 0 35 6 48 20 11 12 17 28 17 48 0 19-6 36-17 48a61 61 0 01-48 20c-19 0-35-7-47-20a69 69 0 01-17-48c0-20 5-36 17-48 12-14 28-20 47-20zm0 118c14 0 25-5 34-15 7-9 11-21 11-35s-4-26-11-35c-9-10-20-15-34-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm107-116v21c5-7 11-12 18-17 6-4 14-6 23-6 8 0 16 1 22 4 6 2 12 6 17 11 10 10 16 24 16 42v77h-20v-76c0-13-3-22-10-29-7-8-16-11-26-11a38 38 0 00-40 40v76h-19V87h19zm222 111a52 52 0 01-46 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 5-35 17-48 12-14 27-20 47-20 19 0 35 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm114 16h-19V34h19v185zm108 0h-19V44h19v175zm55-132v21c5-7 10-12 17-17 7-4 15-6 23-6 9 0 17 1 23 4 6 2 12 6 16 11 11 10 16 24 16 42v77h-19v-76c0-13-4-22-10-29-7-8-16-11-27-11a38 38 0 00-39 40v76h-19V87h19zm202 35c-2-13-13-20-33-20s-30 6-30 19c0 5 2 9 6 12 5 2 10 5 16 6l21 5 21 7c7 2 12 6 16 11 5 5 7 11 7 19 0 13-5 23-15 30-9 7-22 10-38 10-18 0-32-4-42-13-9-8-14-18-15-31h20c2 13 8 21 21 25l13 2 13-1 11-3c8-3 12-9 12-17 0-5-2-9-6-12s-10-6-16-7l-21-5-21-7c-7-2-12-6-16-10-4-5-6-11-6-19 0-12 4-22 12-28 9-7 22-10 39-10 15 0 28 4 37 11 8 7 12 16 14 26h-20zm60 97V104h-26V87h26V40h20v47h30v17h-30v115h-20zm89-180v26h-21V39h21zm-21 48h20v132h-20V87zm65 132V104h-26V87h26V40h20v47h30v17h-30v115h-20zm162 0v-21c-4 7-10 12-17 16-7 5-14 7-23 7s-16-1-22-4c-7-2-12-6-17-11a57 57 0 01-16-42V87h20v76c0 12 3 22 10 29 6 7 15 11 26 11a39 39 0 0039-40V87h20v132h-20zm65 0V104h-26V87h26V40h20v47h30v17h-30v115h-20zm124-16c17 0 30-7 37-22h22c-5 12-12 22-22 29-9 7-22 11-38 11-19 0-35-7-47-20a68 68 0 01-18-48c0-20 5-36 17-48 12-14 28-20 47-20 20 0 35 6 48 20 11 12 17 28 17 48v8h-109c1 12 6 22 14 30s19 12 32 12zm-2-100c-12 0-22 4-30 11s-12 17-14 28h88c-1-11-6-21-14-28s-18-11-30-11zm195-52c-9 0-16 2-21 6-4 4-7 11-7 20v10h30v17h-30v115h-19V104h-23V87h23V75c0-14 4-25 12-32 9-7 21-11 36-11h1v19h-2zm75 34c19 0 35 6 47 20 12 12 18 28 18 48 0 19-6 36-18 48a61 61 0 01-47 20c-19 0-35-7-47-20a69 69 0 01-18-48c0-20 6-36 18-48 12-14 28-20 47-20zm0 118c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm156-118v20h-2c-14 0-25 5-34 17-9 11-13 24-13 39v58h-19V87h19v32c4-13 13-23 27-30 6-3 13-4 21-4h1zM1617 293v175h-19v-78h-101v78h-19V293h19v78h101v-78h19zm91 159c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c1 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm187 95a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-36 18-49 11-13 27-19 47-19 19 0 34 7 45 23v-21h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm114 16h-19V283h19v185zm46 0V353h-27v-17h27v-48h19v48h30v17h-30v115h-19zm87-185v73l17-16c7-4 15-6 24-6 8 0 16 1 22 3a58 58 0 0133 54v77h-20v-77c0-12-3-21-10-29-7-7-16-10-26-10a39 39 0 00-40 40v76h-19V283h19zm280 164a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm109-116v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 11 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10a39 39 0 00-39 40v76h-19V336h19zm222 111a52 52 0 01-47 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-74h19v185h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm233-1a56 56 0 0053-36h21c-6 17-15 30-28 39a82 82 0 01-50 16c-25 0-46-9-61-26a92 92 0 01-22-64c0-25 7-46 22-63 15-18 36-26 61-26a78 78 0 0178 54h-21c-4-11-11-19-20-25-10-7-20-10-33-10-12 0-22 2-30 5-9 4-15 9-21 15a73 73 0 00-17 50c0 21 6 37 17 50 12 14 29 21 51 21zm198-4a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 48-19 19 0 34 7 45 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm163-118v19h-2c-14 0-26 6-34 18-9 10-13 23-13 39v58h-19V336h19v32c4-14 13-24 27-30 6-3 13-4 21-4h1zm73 118c18 0 31-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-19 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 18-49s27-19 47-19c19 0 35 6 47 19s17 29 17 49v8h-109c2 12 7 22 15 30s19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm162-40v59h96v19h-96v59h108v19h-127V293h127v19h-108zm189 88l51 68h-25l-37-54-37 54h-25l51-68-48-64h25l34 50 33-50h25l-47 64zm120 52c9 0 16-3 23-7 6-5 11-11 14-19h21c-4 13-12 24-22 32-11 8-24 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19a60 60 0 0161 44h-20c-3-8-8-15-14-19-7-5-14-7-23-7-8 0-15 1-21 4-6 2-10 6-14 10-9 10-13 22-13 36s4 26 13 35c8 10 20 15 35 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-20 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 13-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm105 116h-19V283h19v185zm51 0h-20V283h20v185zm89-16c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c2 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm105-16v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 12 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10s-20 3-28 11c-7 7-11 17-11 29v76h-19V336h19zm185 116a40 40 0 0037-26h21c-4 13-12 24-22 32-11 8-25 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19c15 0 29 4 40 12 10 8 18 18 22 31h-21c-3-7-8-14-15-18-6-5-13-7-22-7-8 0-15 1-21 4-6 2-11 6-15 10-8 10-12 22-12 36s4 26 12 35c9 10 21 15 36 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 18 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-15 28h89c-2-11-6-21-14-28-8-8-18-11-30-11zM412 454c0 16-7 19-18 19h-53c-11 0-20-4-27-13L130 213h-2v242c0 13-6 18-18 18H52c-14 0-20-3-20-18V62c0-16 7-19 20-19h52c13 0 19 3 26 13l184 248h1V61c0-14 7-18 19-18h60c16 0 17 8 17 19v392h1zm197 4c0 7-5 14-14 14h-71c-9 0-14-7-14-14V56c0-8 5-15 14-15h71c9 0 14 7 14 14v403zm415-380l-18 52c-2 6-5 9-9 9l-8-2c-33-16-58-21-87-21-65 0-106 49-106 140 0 98 47 140 107 140 29 0 55-5 84-17l9-3c6 0 9 3 11 10l16 46 2 10c0 6-3 11-12 14-42 16-77 24-125 24-131 0-197-87-197-221S772 32 896 32c45 0 82 9 118 25 9 4 12 8 12 12l-2 9zm336-37c13 0 17 6 16 15l-6 50c-1 13-9 15-24 15h-149v93h140c14 0 19 7 19 17v45c0 12-7 18-18 18h-141v98h161c11 0 18 5 18 17v46c0 11-6 17-17 17h-240c-14 0-21-4-21-19V59c0-11 6-18 16-18h246z" fill="currentColor"></path></svg></a><div class="Header-module--wrapper--2e13D"><div class="Header-module--search--2nfnz"><form id="global-nav-search-form" role="search" action="https://cks.nice.org.uk/search" class="Search-module--search--2wNll"><label class="Search-module--label--1rrog" for="autocomplete">Search CKS</label><div class="Autocomplete-module--ac--2PqiF"><div class="autocomplete__wrapper"><input type="search" id="autocomplete" name="q" class="autocomplete__input autocomplete__input--default" placeholder="Search CKS" data-hj-allow="" maxLength="512" value=""/></div></div><button class="Search-module--button--2FbnI" type="submit" aria-label="Perform search"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="Search-module--icon--2JB42" aria-hidden="true" focusable="false"><path d="M83.784 476.472L197.112 363.16c30.144 20.32 65.056 30.528 100.032 30.528 45.904 0 91.776-17.488 126.8-52.528 70.064-70.064 70.064-183.584 0-253.616C388.936 52.504 343.048 35 297.144 35c-45.904 0-91.808 17.504-126.848 52.528-61.696 61.696-68.976 157.12-21.968 226.864L35 427.752l48.784 48.72zm213.36-137.952c-33.168 0-64.352-12.896-87.792-36.368-48.416-48.448-48.416-127.2 0-175.616 23.44-23.44 54.64-36.352 87.792-36.352s64.336 12.912 87.776 36.368c23.44 23.456 36.384 54.64 36.384 87.792s-12.928 64.352-36.384 87.792c-23.456 23.472-54.624 36.368-87.776 36.368v.016z" fill="currentColor"></path></svg></button></form></div><button class="Header-module--mobileMenuBtn--1LgyL" id="header-menu-button" type="button" aria-controls="header-menu" aria-expanded="false" aria-haspopup="menu" aria-label="Expand site menu">Menu</button></div></div><div id="header-menu" class="Nav-module--wrapper--2_xng Nav-module--wrapperWithSubLinks--3PUfX"><nav class="Nav-module--nav--2aQpa" aria-label="primary navigation"><div class="Nav-module--menuWrapper--2fp8S"><ul class="Nav-module--menuList--264L-" aria-labelledby="header-menu-button"><li><a href="https://pathways.nice.org.uk/" class="Nav-module--link--3JzDA">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Nav-module--link--3JzDA">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Nav-module--link--3JzDA">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Nav-module--link--3JzDA">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary">BNF<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Nav-module--link--3JzDA"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">Clinical Knowledge Summaries</span></a><div class="SubNav-module--wrapper--yAXWY"><ul class="SubNav-module--list--1K9bK" aria-label="CKS links"><li class="SubNav-module--imageLink--3xwIS"><a href="../../../../index.html" class="SubNav-module--link--39i23" aria-label="CKS - Home"><img src="data:image/svg+xml;base64,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" class="SubNav-module--image--uq-a2" alt=""/></a></li><li><a href="../../../index.html" class="SubNav-module--link--39i23" aria-label="Health topics A to Z">Health topics A to Z</a></li><li><a href="../../../../specialities/index.html" class="SubNav-module--link--39i23" aria-label="Specialities">Specialities</a></li><li><a href="../../../../whats-new/index.html" class="SubNav-module--link--39i23" aria-label="What&#x27;s new">What&#x27;s new</a></li><li><a href="../../../../about/index.html" class="SubNav-module--link--39i23" aria-label="About CKS">About CKS</a></li></ul></div></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Nav-module--link--3JzDA">Journals and databases</a></li></ul></div></nav></div></header><aside class="CoronaMessage-module--wrapper--zRiaV" aria-label="COVID-19 Notice"><div class="CoronaMessage-module--container--36Biz"><p>Read about<!-- --> <a href="https://www.nice.org.uk/covid-19">our approach to COVID-19</a></p></div></aside></div></div><main class="Layout-module--main--1OIFf" id="content-start"><div class="container"><nav aria-label="Breadcrumbs" role="navigation"><ol class="breadcrumbs"><li class="breadcrumbs__crumb"><a href="https://www.nice.org.uk/">NICE</a></li><li class="breadcrumbs__crumb"><a href="../../../../index.html">CKS</a></li><li class="breadcrumbs__crumb"><a href="../../../index.html">Health topics A to Z</a></li><li class="breadcrumbs__crumb"><a href="../../index.html">Diarrhoea - antibiotic associated</a></li><li class="breadcrumbs__crumb"><a href="../index.html">Management</a></li><li class="breadcrumbs__crumb"><span>Scenario: Diarrhoea - antibiotic associated</span></li></ol></nav><script type="application/ld+json">{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.nice.org.uk/","name":"NICE"}},{"@type":"ListItem","position":2,"item":{"@id":"/","name":"CKS"}},{"@type":"ListItem","position":3,"item":{"@id":"/topics/","name":"Health topics A to Z"}},{"@type":"ListItem","position":4,"item":{"@id":"/topics/diarrhoea-antibiotic-associated/","name":"Diarrhoea - antibiotic associated"}},{"@type":"ListItem","position":5,"item":{"@id":"/topics/diarrhoea-antibiotic-associated/management/","name":"Management"}},{"@type":"ListItem","position":6,"item":{"name":"Scenario: Diarrhoea - antibiotic associated"}}]}</script><div class="page-header"><h1 class="page-header__heading"><span class="page-header__pre-heading">Diarrhoea - antibiotic associated: </span><span>Scenario: Diarrhoea - antibiotic associated</span></h1><p class="page-header__lead"><span>Last revised in November 2020</span></p></div><p class="visually-hidden">Covers the management of antibiotic associated diarrhoea.</p><div class="ChapterContents-module--wrapper--3ONbu"><div class="ChapterContents-module--menu--3Epka"><nav class="stacked-nav" aria-label="Diarrhoea - antibiotic associated chapters"><ul class="stacked-nav__list"><li class="stacked-nav__list-item" data-tracking="Summary"><a aria-current="false" href="../../index.html"><span class="stacked-nav__content-wrapper">Summary</span></a></li><li class="stacked-nav__list-item" data-tracking="Have I got the right topic?"><a aria-current="false" href="../../have-i-got-the-right-topic/index.html"><span class="stacked-nav__content-wrapper">Have I got the right topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="How up-to-date is this topic?"><a aria-current="false" href="../../how-up-to-date-is-this-topic/index.html"><span class="stacked-nav__content-wrapper">How up-to-date is this topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="Goals and outcome measures"><a aria-current="false" href="../../goals-outcome-measures/index.html"><span class="stacked-nav__content-wrapper">Goals and outcome measures</span></a></li><li class="stacked-nav__list-item" data-tracking="Background information"><a aria-current="false" href="../../background-information/index.html"><span class="stacked-nav__content-wrapper">Background information</span></a></li><li class="stacked-nav__list-item" data-tracking="Management"><a aria-current="false" href="../index.html"><span class="stacked-nav__content-wrapper">Management</span></a><ul class="stacked-nav__nested"><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Diarrhoea - antibiotic associated"><a aria-current="true" class="" href="index.html"><span class="stacked-nav__content-wrapper">Scenario: Diarrhoea - antibiotic associated</span></a></li></ul></li><li class="stacked-nav__list-item" data-tracking="Prescribing information"><a aria-current="false" href="../../prescribing-information/index.html"><span class="stacked-nav__content-wrapper">Prescribing information</span></a></li><li class="stacked-nav__list-item" data-tracking="Supporting evidence"><a aria-current="false" href="../../supporting-evidence/index.html"><span class="stacked-nav__content-wrapper">Supporting evidence</span></a></li><li class="stacked-nav__list-item" data-tracking="How this topic was developed"><a aria-current="false" href="../../how-this-topic-was-developed/index.html"><span class="stacked-nav__content-wrapper">How this topic was developed</span></a></li><li class="stacked-nav__list-item" data-tracking="References"><a aria-current="false" href="../../references/index.html"><span class="stacked-nav__content-wrapper">References</span></a></li></ul></nav></div><div class="ChapterContents-module--onThisPage--1333P"><nav class="ChapterOnThisPage-module--wrapper--2zc7n" aria-labelledby="on-this-page"><h2 class="ChapterOnThisPage-module--heading--2SdDN" id="on-this-page">On this page</h2><ol class="ChapterOnThisPage-module--rootList--2II70" aria-label="Jump links to section on this page"><li><a href="index.html#assessment">Assessment</a><ol aria-label="Sections within Assessment" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#severity-of-c-difficile">Severity of C. difficile</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-cde">Basis for recommendation</a></li></ol></li><li><a href="index.html#testing">Testing</a><ol aria-label="Sections within Testing" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-3f0">Basis for recommendation</a></li></ol></li><li><a href="index.html#c-difficile-not-suspected-or-awaiting-result">C.difficile not suspected or awaiting result</a><ol aria-label="Sections within C.difficile not suspected or awaiting result" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-fdf">Basis for recommendation</a></li></ol></li><li><a href="index.html#known-c-difficile-test-result-negative">Known C. difficile test resultnegative</a><ol aria-label="Sections within Known C. difficile test resultnegative" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-8d7">Basis for recommendation</a></li></ol></li><li><a href="index.html#known-c-difficile-test-result-positive">Known C. difficile test resultpositive</a><ol aria-label="Sections within Known C. difficile test resultpositive" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-1e8">Basis for recommendation</a></li></ol></li></ol></nav></div><div class="ChapterContents-module--body--1XBoo"><section aria-labelledby="diarrhoea-antibiotic-associated" class="ChapterBody-module--wrapper--2HCfk "><h2 id="diarrhoea-antibiotic-associated" class="visually-hidden">Scenario: Diarrhoea - antibiotic associated</h2><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item aad53950-dfdb-49cc-b412-b22bfd3e0884 --><!-- begin field 3073660c-49f6-4e41-800a-acbc015a13c1 --><p>From age 18 years onwards.</p><!-- end field 3073660c-49f6-4e41-800a-acbc015a13c1 --><!-- end item aad53950-dfdb-49cc-b412-b22bfd3e0884 --></div><section aria-labelledby="assessment" class="ChapterBody-module--wrapper--2HCfk "><h3 id="assessment">How should I assess someone presenting with suspected antibiotic-associated diarrhoea?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item bdac8c77-96a1-4483-908d-1191f9e6a543 --><!-- begin field 0482ef1e-efc1-46d3-9a9a-99c54e49d498 --><ul><li><strong>Assess the severity of the symptoms and consider whether hospital admission is appropriate.</strong><ul><li>For moreinformation on assessing symptoms (including the risk of dehydration) and when to admit, see the CKS topic on<a class="topic-reference external-reference" href="../../../diarrhoea-adults-assessment/index.html">Diarrhoea - adult&#39;s assessment</a>.</li></ul></li><li><strong>Exclude other potential causes of diarrhoea or contributing factors. </strong><ul><li>For more information, see the CKS topic on<a class="topic-reference external-reference" href="../../../diarrhoea-adults-assessment/index.html">Diarrhoea - adult&#39;s assessment</a>.</li></ul></li><li><strong>Check which antibiotics were prescribed and the duration of treatment.</strong><ul><li><em>Clostridiumdifficile</em>infection is more common with certain antibiotics (for more information, see<a class="topic-reference internal-reference" href="../../background-information/risk-factors/index.html">Risk factors</a>).</li></ul></li><li><strong>Consider the possibility of<em>C.difficile</em>infection.</strong><ul><li>There are no clinical symptoms that are specific for<em>C. difficile</em>infection.</li><li>However, suspect the possibility of<em>C.difficile</em>infection (particularly if the person is elderly) if<a class="topic-reference internal-reference" href="../../background-information/risk-factors/index.html">risk factors</a>are present.<ul><li>For information on assessing the severity of<em>C.difficile</em>infection, see<a class="topic-reference internal-reference" href="index.html#severity-of-c-difficile">Severity of C. difficile</a>.</li></ul></li><li>Check for any history of<em>C.difficile</em>infection  as the rate of<a class="topic-reference internal-reference" href="../../background-information/prognosis/index.html">recurrence</a>is high.</li><li>Send a stool sample to test for<em>C.difficile</em>(for further information, see<a class="topic-reference internal-reference" href="index.html#testing">Testing</a>).</li><li>Check whether other cases of<em>C.difficile</em>infection have been reported recently  for example, within the care home or in the hospital ward from which the individual has been recently discharged.<em>C.difficile</em>-associated disease can occur in outbreaks.</li></ul></li></ul><!-- end field 0482ef1e-efc1-46d3-9a9a-99c54e49d498 --><!-- end item bdac8c77-96a1-4483-908d-1191f9e6a543 --></div><section aria-labelledby="severity-of-c-difficile" class="ChapterBody-module--wrapper--2HCfk "><h4 id="severity-of-c-difficile">Severity of Clostridium difficile</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 8e01e5f9-3a17-4b89-9069-50d7b4625d50 --><!-- begin field 434e7893-e942-4232-a1d7-fc2b0494453f --><p><strong>Severity of<em>Clostridium difficile</em>infection can be defined as </strong>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Public Health England, 2013</a>]<strong>:</strong></p><ul><li><strong>Mild:</strong>not associated with an increased white cell count (WCC). It is typically associated with less than three episodes of loose stools (defined as loose enough to take the shape of the container used to sample it) per day.</li><li><strong>Moderate:</strong>associated with an increased WCC (but less than 15x10<sup>9</sup>/L) and typically associated with 35loose stools per day.</li><li><strong>Severe:</strong>associated with a WCC greater than 15x10<sup>9</sup>/L, or an acutely increased serum creatinine concentration (that is, greater than 50% increase above baseline), or a temperature higher than 38.5C, or evidence of severe colitis (abdominal or radiological signs). The number of stools may be a less reliable indicator of severity.</li><li><strong>Life-threatening:</strong>signs and symptoms include hypotension, partial or complete ileus, toxic megacolon, or computerised tomography (CT) evidence of severe disease.</li></ul><!-- end field 434e7893-e942-4232-a1d7-fc2b0494453f --><!-- end item 8e01e5f9-3a17-4b89-9069-50d7b4625d50 --></div></section><section aria-labelledby="basis-for-recommendation-cde" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-cde">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item cde446a6-b118-4ed6-9f4a-cca1a38b1df5 --><!-- begin field a9ffea4d-13c5-47f0-9a96-7b45c5f7deca --><h5>Assess severity of symptoms and consider hospital admission</h5><ul><li>The recommendation to assess severity of symptoms is based on guidance issued by Public Health England on the management and treatment of<em>C. difficile</em>infection asthis will influence treatment decisions[<a class="bibliography-reference internal-reference" href="../../references/index.html">Public Health England, 2013</a>].A North American practice parameter on <em>C. difficile</em> infection also advises a thorough evaluation to determine severity of symptoms and identify sepsis[<a class="bibliography-reference internal-reference" href="../../references/index.html">Steele et al, 2015</a>].In some people with<em>C. difficile</em>infection, dehydration, shock, hypotension, tachycardia, and peritoneal signs may be present[<a class="bibliography-reference internal-reference" href="../../references/index.html">Ong et al, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Guh and Kutty, 2018</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Hassoun, 2018</a>].</li><li>Therecommendation on considering hospital admissionis extrapolated from information in review articles discussing when specialist opinion, interventions, or surgery may be required for<em>C. difficile</em>infection based on the severity of symptoms[<a class="bibliography-reference internal-reference" href="../../references/index.html">Kazanowski et al, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Ong et al, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Sams and Kennedy-Malone, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Guh and Kutty, 2018</a>].</li></ul><h5>Exclude other potential causes of diarrhoea or contributing factors</h5><ul><li>This recommendation reflects guidanceissued by Public Health England and Health Protection Scotland covering the prevention,management, and treatment of<em>C. difficile</em>infection[<a class="bibliography-reference internal-reference" href="../../references/index.html">Public Health England, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Health Protection Scotland, 2017</a>].Expert opinion in a review article also advises considering other infectious and non-infectious causes if a person has diarrhoea and negative tests for<em>C. difficile</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Guh and Kutty, 2018</a>].</li></ul><h5>Check which antibiotics were prescribed</h5><ul><li>This recommendation is consistent with information in a NICE evidence summary on the risk of<em>C. difficile</em>with broad-spectrum antibiotics[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015b</a>],Public Health England diagnostic guidance[<a class="bibliography-reference internal-reference" href="../../references/index.html">PHE, 2018a</a>],and North Americanpractice parameters[<a class="bibliography-reference internal-reference" href="../../references/index.html">Steele et al, 2015</a>].</li><li>The most frequentlyimplicated antibiotics include broad-spectrum penicillins, cephalosporins, clindamycin, and flouroquinolones, but most antibiotics have been associated with<em>C. difficile</em>infection[<a class="bibliography-reference internal-reference" href="../../references/index.html">Leffler and Lamont, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Steele et al, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Trubiano et al, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Sams and Kennedy-Malone, 2017</a>]. The risk of<em>C. difficile</em>infection is increased with greater number of antimicrobials used, higher doses, and longer duration of treatment[<a class="bibliography-reference internal-reference" href="../../references/index.html">Winslow et al, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Trubiano et al, 2016</a>].</li></ul><h5>Consider the possibility of <em>C. difficile </em>infection</h5><ul><li>CKS has advised considering the possibility of<em>C. difficile</em>infection in a person with antibiotic-associated diarrhoea based onguidance issued by Public Health England on the management and treatment of<em>C. difficile</em>infection [<a class="bibliography-reference internal-reference" href="../../references/index.html">Public Health England, 2013</a>],a NICE evidence summary[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015b</a>],and Canadian evidence review[<a class="bibliography-reference internal-reference" href="../../references/index.html">CADTH, 2018a</a>].<ul><li>Antibiotic-associated diarrhoea is associated with<em>C. difficile</em>infection because the changes in normal microflora allows colonization and infection with<em>C. difficile</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">PHE, 2018a</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">CADTH, 2018a</a>]. Antibiotic use isthe major risk factor for<em>C. difficile</em>infection[<a class="bibliography-reference internal-reference" href="../../references/index.html">Steele et al, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Trubiano et al, 2016</a>],and the use of broad-spectrum antibiotics increases the incidence (<em>C. difficile</em>infection is the most common identifiable cause of antibiotic-associated diarrhoea, accounting for around 2030% of cases)[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015b</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">PHE, 2018a</a>].<strong></strong></li><li>Antibiotic-related diarrhoea with<em>C. difficile</em>infection commonly develops during, or shortly after antibiotic treatment[<a class="bibliography-reference internal-reference" href="../../references/index.html">Guh and Kutty, 2018</a>].</li></ul></li></ul><h5>Clinical symptoms of <em>C. difficile</em> infection</h5><ul><li>Symptoms of<em>C. difficile</em>infection can vary from mild diarrhoea to more severe symptoms indicative ofpseudomembranouscolitis,toxic megacolon, bowel perforation, and sepsis[<a class="bibliography-reference internal-reference" href="../../references/index.html">Winslow et al, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Ong et al, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Health Protection Scotland, 2017</a>]. Although<em>C. difficile</em>infection almost always causes diarrhoea,abdominal distension, and pain, other symptoms such as nausea, vomiting, and fever may not be present. Physical findings can be non-specific and depend on the severity and duration of illness[<a class="bibliography-reference internal-reference" href="../../references/index.html">Steele et al, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Guh and Kutty, 2018</a>].</li></ul><h5>Suspect the possibility of <em>C. difficile</em> infection if risk factors are present</h5><ul><li>Older adults are most at risk from<em>C. difficile</em>-associated diarrhoea, particularly if they have a history of recent antibiotic use. Other risk factors also contribute to the chances of developing<em>C. difficile</em>infection[<a class="bibliography-reference internal-reference" href="../../references/index.html">Burke, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Kazanowski et al, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Winslow et al, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Leffler and Lamont, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Steele et al, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Sams and Kennedy-Malone, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Guh and Kutty, 2018</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Hassoun, 2018</a>].<strong></strong></li></ul><h5>Check for a history of <em>C. difficile</em> infection</h5><ul><li>A systematic review and meta-analysis of risk factors for<em>C. difficile</em>infection found that symptomatic recurrence after the primary episode has completely resolved is a frequent complication[<a class="bibliography-reference internal-reference" href="../../references/index.html">Deshpande et al, 2015</a>].Recurrence risk increases with increasing age and a small proportion of people have repeated relapses[<a class="bibliography-reference internal-reference" href="../../references/index.html">Sams and Kennedy-Malone, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Hassoun, 2018</a>]. </li></ul><h5>Stool testing for <em>C. difficile</em> toxin</h5><ul><li><em>C. difficile</em>infection is difficult to diagnose on the basis of physical examination alone, and therefore the diagnosis should be based on clinical signs and symptoms and supported by laboratory tests, including stool studies[<a class="bibliography-reference internal-reference" href="../../references/index.html">An Roinn Slainte, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Steele et al, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Crobach et al, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Trubiano et al, 2016</a>].</li></ul><h5>Check for reports of other cases</h5><ul><li><em>C. difficile</em>has been associated with outbreaks in hospitals and care facilities, especially in people of advanced age[<a class="bibliography-reference internal-reference" href="../../references/index.html">Sams and Kennedy-Malone, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">PHE, 2018a</a>].The index of suspicion for<em>C. difficile</em>infection is increased by a history of recent sick contacts (for example in a nursing home orhospital)[<a class="bibliography-reference internal-reference" href="../../references/index.html">Steele et al, 2015</a>].</li></ul><!-- end field a9ffea4d-13c5-47f0-9a96-7b45c5f7deca --><!-- end item cde446a6-b118-4ed6-9f4a-cca1a38b1df5 --></div></section></section><section aria-labelledby="testing" class="ChapterBody-module--wrapper--2HCfk "><h3 id="testing">What tests should I perform if a Clostridium difficile infection is suspected?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 735cef00-373a-4097-827a-4caa45045d0f --><!-- begin field bb14d13b-63c9-425e-8e44-698b794c222b --><p><strong>For adults with suspected <em>Clostridium difficile </em>infection:</strong></p><ul><li><strong>Send a stool sample to test for<em>C.difficile</em></strong><strong>infection</strong>if the person is symptomatic with liquid/loose stools (with a consistency that takes the shape of the container ideally 1/4 filled) that is not clearly attributable to another condition or therapy,and<em>C. difficile</em>infection is suspected,for example if the person:<ul><li>Has been in contact with a person with <em>C. difficile</em> infection.</li><li>Has recently had a course of antibiotics, proton-pump inhibitor treatment, or been in hospital.</li></ul></li><li><strong><em>Do not</em></strong>wait to initiate sampling or testing as any delay may increase the severity of the disease and the risk of<em>C.difficile</em>transmission.</li><li><strong>Ensure the following details are stated on the request form:</strong><ul><li>Clinical features (for examplenature and durationof symptoms).</li><li>Recent antibiotic or proton pump inhibitor, or hospital admission.</li><li>Contact with other affected individuals or outbreak.</li><li>Underlying illness.</li><li>State if the test was requested by the Health Protection Team, a Consultant in Communicable Disease Control, or a Consultant in Health Protection.</li></ul></li><li><strong>Check the full blood count and serum creatinine</strong> in order to help assess the<a class="topic-reference internal-reference" href="index.html#severity-of-c-difficile">severity</a>of<em>C. difficile</em>.</li><li><strong>Consider re-testing if the first test is negative and there is a strong clinical suspicion of<em>C.difficile</em>infection  seek advice from a consultant medical microbiologist or infection control doctor.</strong></li><li><strong><em>Do not</em> re-test people with a positive<em>C.difficile</em>infection if they are still symptomatic within the same episode.</strong></li><li><strong>Only re-test to confirm recurrent<em>C.difficile</em>infection if the symptoms resolve and then recur.</strong></li><li><strong><em>Do not</em> test to confirm cure.</strong></li><li>For more information on how to advise the person to take a stool sample, see the section on<a class="topic-reference external-reference" href="../../../diarrhoea-adults-assessment/management/acute-diarrhoea-less-than-4-weeks/index.html#sending-a-stool-sample">Collection of stool samples</a>in the CKS topic on<a class="topic-reference external-reference" href="../../../diarrhoea-adults-assessment/index.html">Diarrhoea - adult's assessment</a>.</li></ul><!-- end field bb14d13b-63c9-425e-8e44-698b794c222b --><!-- end item 735cef00-373a-4097-827a-4caa45045d0f --></div><section aria-labelledby="basis-for-recommendation-3f0" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-3f0">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 3f086a09-d0f8-45b7-a3d0-c55a5ad19ac7 --><!-- begin field 58b176ac-b36b-4b4c-a9a5-d996a8dc461c --><h5>Laboratory confirmation of <em>Clostridium difficile</em> infection</h5><ul><li>Laboratory testing of stool is required because <em>Clostridium difficile</em> infection has no distinguishing clinical features from other causes of acute diarrhoea[<a class="bibliography-reference internal-reference" href="../../references/index.html">Trubiano et al, 2016</a>]. Therefore diagnosis is usuallymade on the basis of clinical history, symptomsand signs, and stool testing[<a class="bibliography-reference internal-reference" href="../../references/index.html">An Roinn Slainte, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Debast et&nbsp;al, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Crobach et al, 2016</a>].<strong></strong></li><li>British Society of Gastroenterology and Department of Health guidelines state that when testing for <em>C. difficile</em> infection, a standardised two-stage approach is recommended. This identifies the organism withglutamate dehydrogenase enzyme immunoassay (EIA), nucleic acid amplification testing, or PCR; then toxin EIA is performed to identify active <em>C. difficile</em> toxin production. This combination of a sensitive followed byspecific test produces high negative and positive predictive values when the test results agree[<a class="bibliography-reference internal-reference" href="../../references/index.html">DH, 2012</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Arasaradnam et al, 2018</a>].</li><li>When interpreting the laboratory results [<a class="bibliography-reference internal-reference" href="../../references/index.html">DH, 2012</a>]:<ul><li>If GDH EIA (or NAAT) is positive, and toxin EIA is positive (positive predictive value [PPV] = 91.4%), then<em>C. difficile</em>is most likely to be present.</li><li>If GDH EIA is negative, and toxin EIA is negative (negative predictive value [NPV] = 98.9%) then<em>C. difficile</em>is very unlikely to be present.</li><li>If GDH EIA (or NAAT) is positive, and toxin EIA is negative, then<em>C. difficile</em>could be present (potential<em>C. difficile</em>excretors).</li></ul></li></ul><h5>When to send a stool sample to test for <em>C. difficile</em> infection</h5><ul><li>The recommendation on when to send a stool sample to test for<em> C. difficile </em>infectionis based on guidance issued by Public Health England on managing suspected infectious diarrhoea[<a class="bibliography-reference internal-reference" href="../../references/index.html">PHE, 2015</a>]and the Department of Health's <em>Updated guidance on the diagnosis and reporting of Clostridium difficile</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">DH, 2012</a>].<ul><li>Testing of asymptomatic people is not recommended; it is important to onlysend unformed stools for testingbecause colonisation with <em>C. difficile</em> is relatively common[<a class="bibliography-reference internal-reference" href="../../references/index.html">Crobach et al, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Trubiano et al, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Health Protection Scotland, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Ong et al, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">McDonald et al, 2018</a>].<strong></strong></li><li>Public Health England and the Department of Health recommendstool collection from symptomatic patients as soon as possible because the results may be used to reduce the risk of transmission of <em>C. difficile</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">DH, 2012</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Public Health England, 2013</a>].This is consistent with advice from Health Protection Scotland and the Irish Department of Health[<a class="bibliography-reference internal-reference" href="../../references/index.html">An Roinn Slainte, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Health Protection Scotland, 2017</a>].</li></ul></li></ul><h5>Request form details</h5><ul><li>The recommendation to describe the clinical features is pragmatic and based on information in a Health Protection Scotland guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Health Protection Scotland, 2017</a>].Other features to document are extrapolated from PHE guidance on managing suspected infectious diarrhoea[<a class="bibliography-reference internal-reference" href="../../references/index.html">PHE, 2015</a>], and risk factors for <em>C. difficile</em> infectionoutlined by North American and Scottish experts[<a class="bibliography-reference internal-reference" href="../../references/index.html">Health Protection Scotland, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">McDonald et al, 2018</a>] and expert opinion in a review article[<a class="bibliography-reference internal-reference" href="../../references/index.html">Sams and Kennedy-Malone, 2017</a>].</li></ul><h5>Check full blood count and creatinine</h5><ul><li>A full blood count (may show leukocytosis) and creatinine level can be useful in assessing the severity of disease and identifying the presence of complications[<a class="bibliography-reference internal-reference" href="../../references/index.html">Steele et al, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Guh and Kutty, 2018</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Hassoun, 2018</a>].</li></ul><h5>Retesting </h5><ul><li><strong>Re-testonly if the first test is negative and there is a strong clinical suspicion of<em>C.difficile</em>infection  seek specialist advice</strong><ul><li>CKS recommends seeking advice from a microbiologist on whether retesting is indicated, based on opinion from experts:<ul><li>Health Protection Scotland guidance on obtaining stool specimens notes that a negative test result does not necessarily exclude infection, particularly if clinical symptoms are highly indicative, and advises discussion with a consultant medical microbiologist or infection control doctor[<a class="bibliography-reference internal-reference" href="../../references/index.html">Health Protection Scotland, 2017</a>].</li><li>European diagnostic guidance for <em>C. difficile</em> and North American clinical practice guidelines for <em>C. difficile</em> infection also discuss the potential value of repeated testing after a negative sample if there is a high clinical suspicion[<a class="bibliography-reference internal-reference" href="../../references/index.html">Crobach et al, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">McDonald et al, 2018</a>].</li></ul></li></ul></li><li><strong>Do not re-test people with a positive<em>C.difficile</em>infection if they are still symptomatic during the same episode</strong><ul><li>If there has been a positive sample, repeated testing during the same episodeof diarrhoea is not recommended byHealth Protection Scotland guidelines on prevention and treatment of <em>C. difficile</em> infection[<a class="bibliography-reference internal-reference" href="../../references/index.html">Health Protection Scotland, 2017</a>]. This is consistent with Irish Department of Health guidelines that advise against retesting when a person is on treatment for <em>C. difficile</em>infection [<a class="bibliography-reference internal-reference" href="../../references/index.html">An Roinn Slainte, 2014</a>],and North American guidelines that do not recommend repeat testing (within 7 days) during the sameepisode of diarrhoea[<a class="bibliography-reference internal-reference" href="../../references/index.html">McDonald et al, 2018</a>].</li></ul></li><li><strong>Only re-test to confirm recurrent<em>C.difficile</em>infection if the symptoms resolve and then recur</strong><ul><li>North American guidelines advise testing (including toxin detection) if recurrent <em>C. difficile</em> infection is suspected after diarrhoea has stopped with successful treatment[<a class="bibliography-reference internal-reference" href="../../references/index.html">McDonald et al, 2018</a>]. This is consistent with Health Protection Scotland and the Irish Department of Health who recommend repeat testing if recurrent diarrhoea occurs after a symptom-free interval in a person with recent <em>C. difficile </em>infection[<a class="bibliography-reference internal-reference" href="../../references/index.html">An Roinn Slainte, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Health Protection Scotland, 2017</a>].</li></ul></li><li><strong>Test of cure</strong><ul><li>UK, European, North American, and Australasianexperts agree that a test of cure after treatment is not recommended[<a class="bibliography-reference internal-reference" href="../../references/index.html">An Roinn Slainte, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Crobach et al, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Leffler and Lamont, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Trubiano et al, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Health Protection Scotland, 2017</a>].<ul><li>Positive tests can occur for weeks or months after symptoms resolve despite successful treatment, with asymptomatic carriage of <em>C.difficile</em> estimated at around 2530% one month post-treatment[<a class="bibliography-reference internal-reference" href="../../references/index.html">Kazanowski et al, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Leffler and Lamont, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Trubiano et al, 2016</a>].</li></ul></li></ul></li></ul><!-- end field 58b176ac-b36b-4b4c-a9a5-d996a8dc461c --><!-- end item 3f086a09-d0f8-45b7-a3d0-c55a5ad19ac7 --></div></section></section><section aria-labelledby="c-difficile-not-suspected-or-awaiting-result" class="ChapterBody-module--wrapper--2HCfk "><h3 id="c-difficile-not-suspected-or-awaiting-result">How should I manage antibiotic-associated diarrhoea if C.difficile infection is not suspected or while awaiting the result of C.difficile testing?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item d1152878-ecb4-420e-9f47-de155305ca16 --><!-- begin field f0400857-cb4d-473f-b3f3-a4cf9dd6fbc1 --><p><strong>For people in whom <em>Clostridium difficile </em>infection is not suspected, or while awaiting a <em>C. difficile </em>test result:</strong></p><ul><li><strong>Assess the severity of the condition and consider whether hospital admission is appropriate</strong>(for further information, see the section on<a class="topic-reference external-reference" href="../../../diarrhoea-adults-assessment/management/acute-diarrhoea-less-than-4-weeks/index.html#admission-or-referral">Admission or referral</a>in theCKS topic on <a class="topic-reference external-reference" href="../../../diarrhoea-adults-assessment/index.html">Diarrhoea - adult's assessment</a>).</li><li><strong>If hospital admission is not required:</strong><ul><li>Stop the antibiotic, if this is appropriate.<ul><li>Seek specialist advice if it is not appropriate to stop the antibiotic and the diarrhoea is severe.</li></ul></li><li>If highly suspicious that the person has<em>C.difficile</em>infection,<a class="topic-reference internal-reference" href="index.html#severity-of-c-difficile">assess the severity</a>and consider seeking specialist advice on whether an empirical<a class="topic-reference internal-reference" href="index.html#known-c-difficile-test-result-positive">antibiotic</a>should be offered.</li><li>Manage fluid loss and symptoms as for acute gastroenteritis (for further information, see the CKS topic on<a class="topic-reference external-reference" href="../../../gastroenteritis/index.html">Gastroenteritis</a>).</li><li>Avoid the use of antimotility drugs (such as loperamide) to treat diarrhoeal symptoms while awaiting<em>C.difficile</em>results.</li><li>Give advice on hygiene measures to minimize the spread of possible infection (for further information, see theCKS topic on<a class="topic-reference external-reference" href="../../../gastroenteritis/index.html">Gastroenteritis</a>).</li></ul></li></ul><!-- end field f0400857-cb4d-473f-b3f3-a4cf9dd6fbc1 --><!-- end item d1152878-ecb4-420e-9f47-de155305ca16 --></div><section aria-labelledby="basis-for-recommendation-fdf" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-fdf">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item fdf2c9af-fd3d-42fa-b552-b5a4e4ce1c98 --><!-- begin field 9bdf1b35-b942-4c51-8021-592dfbc4db54 --><h5>Consider whether hospital admission is appropriate</h5><ul><li>This recommendation is pragmatic and based on what CKS considers to be good clinical practice.</li></ul><h5>Management if hospital admission is not required</h5><h5>Stopping the antibiotic</h5><ul><li>A Canadianevidence review mentions reducing the use of antibiotics as a measure for addressing mild cases of antibiotic-associated diarrhoea[<a class="bibliography-reference internal-reference" href="../../references/index.html">CADTH, 2018a</a>].</li><li>For people awaiting <em>Clostridium difficile</em> test results, the recommendation to consider stopping the antibiotic causing diarrhoea is also extrapolated fromPublic Health England (PHE) guidance on the management and treatment of <em>C. difficile</em> infection which recommends that, if possible, antibiotic treatment should be stopped for people with<em>C.difficile</em>infection to allow normal intestinal flora to be re-established[<a class="bibliography-reference internal-reference" href="../../references/index.html">Public Health England, 2013</a>].This is in line with subsequent PHE publications[<a class="bibliography-reference internal-reference" href="../../references/index.html">PHE, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">NICE and PHE, 2019</a>],<strong></strong>guidelines from Ireland[<a class="bibliography-reference internal-reference" href="../../references/index.html">An Roinn Slainte, 2014</a>],North America[<a class="bibliography-reference internal-reference" href="../../references/index.html">Steele et al, 2015</a>],<strong></strong>and Australasia[<a class="bibliography-reference internal-reference" href="../../references/index.html">Trubiano et al, 2016</a>]<strong></strong>and expert opinion in review articles[<a class="bibliography-reference internal-reference" href="../../references/index.html">Winslow et al, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Sams and Kennedy-Malone, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Guh and Kutty, 2018</a>]. </li><li>It is important not to affect recovery from the conditionfor which the initial antibiotic was prescribed[<a class="bibliography-reference internal-reference" href="../../references/index.html">Guh and Kutty, 2018</a>],therefore the decision to stop an antibioticshould be based on the person's clinical state[<a class="bibliography-reference internal-reference" href="../../references/index.html">Steele et al, 2015</a>],and people for whom antibiotic treatment is stopped should be observed closely for signs of clinical deterioration[<a class="bibliography-reference internal-reference" href="../../references/index.html">Debast et&nbsp;al, 2014</a>].If treatment of the original condition is necessary, itmay be possible to select an alternative antibiotic which is less likely to contribute to<em>C. difficile</em> infection[<a class="bibliography-reference internal-reference" href="../../references/index.html">Winslow et al, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Sams and Kennedy-Malone, 2017</a>].</li></ul><h5>Consider seeking specialist advice about empirical antibiotic treatment</h5><ul><li>Guidance on prevention and control of <em>C. difficile</em> infection issued by Health Protection Scotland advises that if <em>C. difficile</em> infection is suspected, confirmation of the diagnosis from laboratory results should not be awaited before initiating treatment[<a class="bibliography-reference internal-reference" href="../../references/index.html">Health Protection Scotland, 2017</a>].This recommendation is also extrapolated from discussion in a systematic review that empirical therapy is only indicated if the results of diagnostic tests are awaited and the probability of infection is high[<a class="bibliography-reference internal-reference" href="../../references/index.html">Kazanowski et al, 2014</a>].</li></ul><h5>Manage fluid loss and symptoms as for acute gastroenteritis</h5><ul><li>European treatment guidance for <em>C. difficile</em> infection suggest adequate replacement of fluid and electrolytes as a treatment measure[<a class="bibliography-reference internal-reference" href="../../references/index.html">Debast et&nbsp;al, 2014</a>].<strong></strong>A practice parameter for the management of <em>C. difficile</em> infection notes the potentialimportance of fluid resuscitation as a factor in limiting severity, duration, and complications[<a class="bibliography-reference internal-reference" href="../../references/index.html">Steele et al, 2015</a>].</li></ul><h5>Avoid the use of antimotility drugs</h5><ul><li>CKS does not recommend the use of antimotility drugs in people with suspected<em>C. difficile</em>infection in line with European treatment guidance for <em>C. difficile</em> infection[<a class="bibliography-reference internal-reference" href="../../references/index.html">Debast et&nbsp;al, 2014</a>],Irish guidance on surveillance, diagnosis and management of <em>C. difficile</em> infection[<a class="bibliography-reference internal-reference" href="../../references/index.html">An Roinn Slainte, 2014</a>]<strong></strong>andexpert opinion in review articles[<a class="bibliography-reference internal-reference" href="../../references/index.html">Ong et al, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Sams and Kennedy-Malone, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Guh and Kutty, 2018</a>].There is a lack of evidence to support their use and there are concerns about possible adverse effects (for example ileus, toxic megacolon)[<a class="bibliography-reference internal-reference" href="../../references/index.html">An Roinn Slainte, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Sams and Kennedy-Malone, 2017</a>].If a person has<em>C. difficile</em> infection, antiperistaltic drugs may also prevent distribution of therapeutic antibiotic in the gut, andaffect expulsion of toxin[<a class="bibliography-reference internal-reference" href="../../references/index.html">Guh and Kutty, 2018</a>].</li></ul><p>Give advice on hygiene measures</p><ul><li>CKS recommends advising on hygiene measures if a <em>C. difficile</em> test result is awaited because Public Health England [<a class="bibliography-reference internal-reference" href="../../references/index.html">Public Health England, 2013</a>] and international guidelines advocate the use of infection control measures, including handwashing and environmental cleaning, to prevent the spread of <em>C. difficile</em> infection[<a class="bibliography-reference internal-reference" href="../../references/index.html">An Roinn Slainte, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Debast et&nbsp;al, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Steele et al, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Trubiano et al, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">McDonald et al, 2018</a>].<ul><li>Hygiene measures are important if a diagnosis is made because the spores of<em>C.difficile</em>are transmissible and can contaminate the environment, where they survive for a long period of time as they are resistant to heat, acid, and chemicals. The spores can be picked up by contact with a person or contaminated surfaceand then swallowed. Carers of a person with <em>C. difficile</em> infection are easily contaminated and hand washing with liquid soap and water is advised to remove spores and prevent their spread as alcohol hand rubs do not kill spores[<a class="bibliography-reference internal-reference" href="../../references/index.html">Steele et al, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Health Protection Scotland, 2017</a>].</li></ul></li></ul><!-- end field 9bdf1b35-b942-4c51-8021-592dfbc4db54 --><!-- end item fdf2c9af-fd3d-42fa-b552-b5a4e4ce1c98 --></div></section></section><section aria-labelledby="known-c-difficile-test-result-negative" class="ChapterBody-module--wrapper--2HCfk "><h3 id="known-c-difficile-test-result-negative">How should I manage antibiotic-associated diarrhoea if C.difficile toxin test is negative?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 4a56f769-e38d-426b-8f98-4dd6212de4af --><!-- begin field 03960e33-35ed-4981-b4cb-b850778cc1a4 --><ul><li><strong>If the<em>Clostridium difficile</em>toxin test result is negative:</strong><ul><li>Continue management as outlined in<a class="topic-reference internal-reference" href="index.html#c-difficile-not-suspected-or-awaiting-result">C.&nbsp;difficile not suspected or awaiting result</a>.</li><li>Consider seeking specialist advice and retesting if there is a strong clinical suspicion of<em>C. difficile</em>infection or if in doubt.</li></ul></li></ul><!-- end field 03960e33-35ed-4981-b4cb-b850778cc1a4 --><!-- end item 4a56f769-e38d-426b-8f98-4dd6212de4af --></div><section aria-labelledby="basis-for-recommendation-8d7" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-8d7">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 8d712ec9-e410-4931-ae99-b06a509e75b1 --><!-- begin field ad07eb62-de55-43f2-858a-83755805cebe --><p><strong>Continue management as outlined in<a class="topic-reference internal-reference" href="index.html#c-difficile-not-suspected-or-awaiting-result">C.&nbsp;difficile not suspected or awaiting result</a>.</strong></p><ul><li>This recommendation is pragmatic and is based on what CKS considers to be good clinical practice.</li></ul><h5>Consider seeking specialist advice and retesting if there is a strong clinical suspicion of <em>C. difficile</em> infection or if in doubt</h5><ul><li>This recommendation is based on expert opinion in a review article advising a specialist opinion if the diagnosis is uncertain[<a class="bibliography-reference internal-reference" href="../../references/index.html">Guh and Kutty, 2018</a>].<strong></strong></li><li>North American clinical practice guidelines for <em>C. difficile</em> infection from the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) advise considering repeat testing in symptomatic people with a negative test for whom there is a high clinical suspicion of <em>C. difficile</em> infection[<a class="bibliography-reference internal-reference" href="../../references/index.html">McDonald et al, 2018</a>].This is consistent with advice in a diagnostic guidance document for <em>C. difficile</em>infection from the European Society of Clinical Microbiology and Infectious Diseases[<a class="bibliography-reference internal-reference" href="../../references/index.html">Crobach et al, 2016</a>]<strong></strong>and Public Health England, who note that one-off negative results can occur[<a class="bibliography-reference internal-reference" href="../../references/index.html">PHE, 2018a</a>].</li></ul><!-- end field ad07eb62-de55-43f2-858a-83755805cebe --><!-- end item 8d712ec9-e410-4931-ae99-b06a509e75b1 --></div></section></section><section aria-labelledby="known-c-difficile-test-result-positive" class="ChapterBody-module--wrapper--2HCfk "><h3 id="known-c-difficile-test-result-positive">How should I manage antibiotic-associated diarrhoea if C.difficile toxin tests are positive?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 53cd507c-1bd4-4f54-b415-562f62c05fba --><!-- begin field abccb27c-5ff3-400b-bc86-a7392198b8b3 --><ul><li><strong>People with features of severe infection should be managed in secondary care.</strong></li><li><strong>For people who have mild-to-moderate<em>C. difficile</em>infection</strong>consult local policy or discuss further management with a microbiologistand consider prescribing an antibiotic:<ul><li>People with mild disease (less than 4 episodes of stool a day) may not require specific<em>C. difficile</em>antibiotic treatment.</li><li>As a guide, Public Health England recommends:<ul><li>For the initial episode of mild-to-moderate<em>C. difficile</em>infection: oral metronidazole 400 mg three times a day for 1014 days.</li><li>Vancomycin and fidaxomicin are reserved for severe<em>C. difficile</em>infection or for subsequent recurrences.</li></ul></li></ul></li><li><strong>Assess whether there is a risk of a<em>C.difficile</em>outbreak</strong> for example, among other elderly residents in a care or nursing home.</li><li><strong>Stop any antibiotics not being used for treating<em>C.difficile</em>infection, if this is appropriate.</strong>Seek specialist advice if this is not possible and the diarrhoea is severe.</li><li><strong>Manage fluid loss as for acute gastroenteritis</strong>(for further information, see the CKS topic on<a class="topic-reference external-reference" href="../../../gastroenteritis/index.html">Gastroenteritis</a>).</li><li><strong>Avoid the use of antimotility drugs</strong>(such as loperamide) to treat diarrhoeal symptoms. If possible, avoid other drugs with anti-peristaltic effects (such as opioids).</li><li><strong>Give advice on hygiene measures to minimize the spread of<em>C. difficile</em></strong>(seethe CKS topic on<a class="topic-reference external-reference" href="../../../gastroenteritis/index.html">Gastroenteritis</a>).<ul><li>Note that alcohol-basedhand rubs are not effective in removing <em>C.difficile</em> spores.</li></ul></li><li><strong>Review the person daily</strong>and monitor for signs of increasing<a class="topic-reference internal-reference" href="index.html#severity-of-c-difficile">severity</a>of disease, as they may deteriorate very rapidly.</li><li><strong>Advise people that:</strong><ul><li>The diarrhoea should resolve in 12weeks.</li><li>They remain infectious while they are still ill and have symptoms.</li><li>They should not return to work or school until they have been free from diarrhoea for 48 hours. If medication is prescribed, they should ensure that the full course is completed and there is no further diarrhoea or vomiting for 48 hours afterwards.</li><li>Once recovered, they should seek medical advice if they develop unexplained diarrhoea, as there is a high rate of recurrence with<em>C.difficile</em>infection.</li></ul></li><li><strong>Offer written information,</strong> such as NHS informationon<a href="https://www.nhs.uk/conditions/c-difficile/" data-hyperlink-id="28e31009-ad54-4384-9825-a9ff00d1ab64">Clostridium difficile infection</a>, available at <a href="https://www.nhs.uk/" data-hyperlink-id="f48b55b4-ec5d-4020-b9dd-a9ff00d1ab78">www.nhs.uk</a>.</li><li><strong>If the person's condition has improved considerably or has resolved without treatment, consider the possibility of a false-positive test result.</strong></li></ul><!-- end field abccb27c-5ff3-400b-bc86-a7392198b8b3 --><!-- end item 53cd507c-1bd4-4f54-b415-562f62c05fba --></div><section aria-labelledby="basis-for-recommendation-1e8" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-1e8">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 1e8a34b1-fff1-4ae0-b861-0ab03e377b8c --><!-- begin field dfcbfaee-f088-4010-9e5e-d3e3c72d5144 --><h5>Manage people with features of severe infection in secondary care</h5><ul><li>CKS has made this recommendation on the basis of guidance from the Irish Department of Health, that suggests people with severe Clostridium difficile infection should be managed by a multidisciplinary team (including a clinical microbiologist and/or infection diseases physician and a surgeon)[<a class="bibliography-reference internal-reference" href="../../references/index.html">An Roinn Slainte, 2014</a>] andexpert opinion in review articles<strong> </strong>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Kazanowski et al, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Sams and Kennedy-Malone, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Guh and Kutty, 2018</a>].<ul><li>Outpatient treatment is not feasible for people with dehydration, hypotension, signs of peritonitis, toxic megacolon, suspected sepsis, or changes in mental state. Admission to intensive care or resuscitation may be required[<a class="bibliography-reference internal-reference" href="../../references/index.html">Ong et al, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Sams and Kennedy-Malone, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Guh and Kutty, 2018</a>].Some people may also need surgical intervention, for example those with peritonitis, or severe and protracted infection leading to toxic megacolon and intestinal perforation and necrosis[<a class="bibliography-reference internal-reference" href="../../references/index.html">Kazanowski et al, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Steele et al, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Ong et al, 2017</a>].</li></ul></li></ul><h5>Antibiotics for treating mild to moderate <em>Clostridium difficile</em> infection</h5><ul><li>The recommendations regarding the choice of antibiotic to treat<em>C. difficile</em>infectionis based on guidance published by Public Health England:<em>Updated guidance on the management and treatment of Clostridium difficile infection</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Public Health England, 2013</a>], <em>Managing suspected infectious diarrhoea</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">PHE, 2015</a>]and <em>Summary of antimicrobial prescribing guidance - managing common infections</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE and PHE, 2019</a>].<ul><li>A Cochrane systematic review of antibiotic treatment for <em>C. difficile</em>-associated diarrhoea in adults identified 22 studies (n = 3215), with most including people with mild to moderate disease. One small randomized controlled trial (RCT) compared vancomycin with placebo for treating<em>C. difficile</em>infections, but it was of low quality, and the lack of other placebo-controlled studies means it is not possible to assess the benefit of antibiotic treatment for <em>C. difficile</em> infection over withdrawal of the initialantibiotic. There is moderate quality evidence to suggest better efficacy of vancomycin compared with metronidazole (symptomatic cure in 79% vs 72%; RR 0.90, 95% CI 0.84 to 0.97), and superiority of fidaxomicin over vancomycin (symptomatic cure in 71% vs 61%; RR 1.17, 95% CI 1.04 to 1.31),although the Cochrane authors noted the relatively small differences in effectiveness and the much lower cost of metronidazole compared with vancomycin and fidaxomicin[<a class="bibliography-reference internal-reference" href="../../references/index.html">Nelson et al, 2017</a>].</li><li>A subsequent systematic review and network meta-analysis of the comparative efficacy of treatments for <em>C. difficile</em> infection (n = 5361) found moderate-to low quality evidence that, for first infections, fidaxomicin is more effective than vancomycin for sustained cure (OR 0.67, 95% CI 0.55to 0.82), with both fidaxomicin and vancomycin offering superior performance compared with metronidazole (ORfor fidaxomicin 0.49, 95% CI 0.35 to 0.68; OR for vancomycin 0.73, 05% CI 0.56 to 0.95) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Beinortas et al, 2018</a>]. This study was discussed in a NICE evidence review in which the authors noted that there were limited relevant data on disease severity, causing difficulty making recommendations related to choice of treatment according to severity of infection, duration of treatment, or management of recurrence. They questioned whether future national recommendations on antibiotic preference should take note of these findings given the relative effectiveness of the different antibiotics [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2018</a>].</li></ul></li></ul><h5>Assess risk of a <em>C. difficile</em> outbreak</h5><ul><li>This recommendation is extrapolated from expert opinion in a review article that outlines the need for awareness of the potential for outbreaks of <em>C. difficile</em> infection in vulnerable populations[<a class="bibliography-reference internal-reference" href="../../references/index.html">Sams and Kennedy-Malone, 2017</a>].Public Health England note the association with outbreaks in hospitals and extended care facilities for the elderly[<a class="bibliography-reference internal-reference" href="../../references/index.html">PHE, 2018a</a>].<strong></strong></li></ul><h5>Stop the antibiotic causing the diarrhoea(apart from any being used to treat the<em>C.difficile</em>infection)</h5><ul><li>The recommendation to consider stopping the antibiotic causing diarrhoea reflects Public Health England guidance on the management and treatment of <em>C. difficile</em> infection which recommends that, if possible, antibiotic treatment should be stopped for people with<em>C.difficile</em>infection to allow normal intestinal flora to be re-established [<a class="bibliography-reference internal-reference" href="../../references/index.html">Public Health England, 2013</a>]. This is in line with subsequent PHE publications[<a class="bibliography-reference internal-reference" href="../../references/index.html">PHE, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">NICE and PHE, 2019</a>],<strong></strong>guidelines from Europe[<a class="bibliography-reference internal-reference" href="../../references/index.html">An Roinn Slainte, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Debast et&nbsp;al, 2014</a>], North America[<a class="bibliography-reference internal-reference" href="../../references/index.html">Steele et al, 2015</a>], and Australasia[<a class="bibliography-reference internal-reference" href="../../references/index.html">Trubiano et al, 2016</a>]<strong>,</strong>and expert opinion in review articles[<a class="bibliography-reference internal-reference" href="../../references/index.html">Winslow et al, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Sams and Kennedy-Malone, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Guh and Kutty, 2018</a>].</li><li>It is important not to affect recovery from the conditionfor which the initial antibiotic was prescribed[<a class="bibliography-reference internal-reference" href="../../references/index.html">Guh and Kutty, 2018</a>],therefore the decision to stop an antibioticshould be based on the person's clinical state[<a class="bibliography-reference internal-reference" href="../../references/index.html">Steele et al, 2015</a>],and people for whom antibiotic treatment is stopped should be observed closely for signs of clinical deterioration[<a class="bibliography-reference internal-reference" href="../../references/index.html">Debast et&nbsp;al, 2014</a>].If treatment of the original condition is necessary, itmay be possible to select an alternative antibiotic which is less likely to contribute to<em>C. difficile</em> infection[<a class="bibliography-reference internal-reference" href="../../references/index.html">Winslow et al, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Sams and Kennedy-Malone, 2017</a>].</li></ul><h5>Manage fluid loss as for acute gastroenteritis</h5><ul><li>Public Health England advises supportive care including attention to hydration and electrolytes[<a class="bibliography-reference internal-reference" href="../../references/index.html">Public Health England, 2013</a>].This recommendation is also supportedby European guidelines[<a class="bibliography-reference internal-reference" href="../../references/index.html">Debast et&nbsp;al, 2014</a>]<strong></strong>and expert opinion in review articles[<a class="bibliography-reference internal-reference" href="../../references/index.html">Hassoun, 2018</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Guh and Kutty, 2018</a>].A practice parameter for the management of <em>C. difficile</em> infection notes the potentialimportance of fluid resuscitation as a factor in limiting severity, duration, and complications[<a class="bibliography-reference internal-reference" href="../../references/index.html">Steele et al, 2015</a>].</li></ul><h5><strong>Avoiding antimotility drugs and drugs with anti-peristaltic effects</strong></h5><ul><li>CKS does not recommend the use of antimotility drugs in people with <em>C. difficile</em>infection in line with Public Health England guidance on the management and treatment of <em>C. difficile</em> infection[<a class="bibliography-reference internal-reference" href="../../references/index.html">Public Health England, 2013</a>],European treatment guidance for <em>C. difficile</em> infection[<a class="bibliography-reference internal-reference" href="../../references/index.html">Debast et&nbsp;al, 2014</a>],Irish guidance on surveillance, diagnosis and management of <em>C. difficile</em> infection[<a class="bibliography-reference internal-reference" href="../../references/index.html">An Roinn Slainte, 2014</a>]<strong></strong>andexpert opinion in review articles[<a class="bibliography-reference internal-reference" href="../../references/index.html">Ong et al, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Sams and Kennedy-Malone, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Guh and Kutty, 2018</a>].<strong></strong>There is a lack of evidence to support their use and there are concerns about possible adverse effects[<a class="bibliography-reference internal-reference" href="../../references/index.html">An Roinn Slainte, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Sams and Kennedy-Malone, 2017</a>]. If a person has<em>C. difficile</em> infection, antiperistaltic drugs may prevent distribution of therapeutic antibiotic in the gut, andaffect expulsion of toxin[<a class="bibliography-reference internal-reference" href="../../references/index.html">Guh and Kutty, 2018</a>].</li><li>This is in line with recommendations from the manufacturer of loperamide, which state that loperamide is contraindicated for people in whom inhibition of peristalsis should be avoided due to the possible risk of significant sequelae including ileus, megacolon, and toxic megacolon (including people with pseudomembranous colitis associated with the use of broad-spectrum antibiotics)[<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018a</a>].</li></ul><h5>Give advice on hygiene measures</h5><ul><li><p>Public Health England guidance on the management and treatment of <em>C. difficile</em> infection[<a class="bibliography-reference internal-reference" href="../../references/index.html">Public Health England, 2013</a>] and otherinternational guidelines advocate the use of infection control measures, including handwashing and environmental cleaning, to prevent the spread of <em>C. difficile</em> infection[<a class="bibliography-reference internal-reference" href="../../references/index.html">An Roinn Slainte, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Debast et&nbsp;al, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Steele et al, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Trubiano et al, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Health Protection Scotland, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">McDonald et al, 2018</a>].</p><ul><li>Hygiene measures are important because the spores of<em>C.difficile</em>are transmissible and can contaminate the environment, where they survive for a long period of time as they are resistant to heat, acid, and chemicals. The spores can be picked up by contact with a person or contaminated surfaceand then swallowed. Carers of a person with <em>C. difficile</em> infection are easily contaminated and hand washing with liquid soap and water is advised to remove spores and prevent their spread as alcohol hand rubs do not kill spores[<a class="bibliography-reference internal-reference" href="../../references/index.html">Steele et al, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Health Protection Scotland, 2017</a>].</li></ul></li></ul><h5>Review the person daily and monitor for signs of increasing severity of disease</h5><ul><li>The recommendation to review daily is based on guidance from Public Health England on the management and treatment of <em>C. difficile</em> infection, which recommends a management plan tailoredto the course and severity of the illness[<a class="bibliography-reference internal-reference" href="../../references/index.html">Public Health England, 2013</a>].This advice is also pragmatic, and based on what CKS considers to be good clinical practice, given that people with severe disease should be managed in secondary care[<a class="bibliography-reference internal-reference" href="../../references/index.html">An Roinn Slainte, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Kazanowski et al, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Ong et al, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Sams and Kennedy-Malone, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Guh and Kutty, 2018</a>].</li><li>European guidelines suggest close follow up for signs of clinical deterioration in people for whom contributing antibiotic treatment has been stopped and therapy for <em>C. difficile</em> infection has not yet commenced[<a class="bibliography-reference internal-reference" href="../../references/index.html">Debast et&nbsp;al, 2014</a>].For people failing to respond to treatment for <em>C.difficile</em> infection,Irish guidelines advise consideration of surgery if there is deterioration in the person'scondition along with systemicinflammation[<a class="bibliography-reference internal-reference" href="../../references/index.html">An Roinn Slainte, 2014</a>].</li></ul><h5>Advise on the time course of the illness</h5><ul><li>The recommendations about the durationof illness and the risk of recurrence of <em>C. difficile</em> infection are based on PHE <em>Updated guidance on the management and treatment of Clostridium difficile infection.</em>The recurrence rate for<em>C.difficile</em>infection is high after the initial episode: around 20% for the first episode and 4560% after the second episode in hospitalised patients[<a class="bibliography-reference internal-reference" href="../../references/index.html">Public Health England, 2013</a>].</li><li>Information on infection risk and avoidance of school or work is extrapolated from PHE guidance on health protection in schools and other childcare facilities for diarrhoea and vomiting [<a class="bibliography-reference internal-reference" href="../../references/index.html">PHE, 2018b</a>]and patient information on leaving hospital for people who have had <em>C. difficile</em> during admission [<a class="bibliography-reference internal-reference" href="../../references/index.html">DH, 2011</a>].</li></ul><h5>Use of probiotics</h5><ul><li>Probiotics arethought to repopulate the gastrointestinal tract and limit the growth of <em>C. difficile </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Guh and Kutty, 2018</a>]. However, they are not recommended by Public Health England or Health Protection Scotland for the treatment of <em>C. difficile</em> infection on the grounds of insufficient evidence[<a class="bibliography-reference internal-reference" href="../../references/index.html">Public Health England, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Health Protection Scotland, 2017</a>] and areview of guidelines from international organisations found that most did notsupport the use of probiotics for prevention or treatment of<em>C. difficile</em> infection[<a class="bibliography-reference internal-reference" href="../../references/index.html">CADTH, 2018b</a>].It is also difficult to make recommendations because ofuncertainties regarding the choice of probiotic, dose, and duration of treatment[<a class="bibliography-reference internal-reference" href="../../references/index.html">Steele et al, 2015</a>].<ul><li>European and North Americanguidelines also noted sparse andinsufficient evidence for the treatment of <em>C. difficile</em> infection[<a class="bibliography-reference internal-reference" href="../../references/index.html">Debast et&nbsp;al, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Steele et al, 2015</a>]. A subsequent evidence reviewfound conflicting evidence for the role of probiotics in prevention and treatment[<a class="bibliography-reference internal-reference" href="../../references/index.html">Wilkins and Sequoia, 2017</a>].A further review of the clinical effectiveness of probiotics for antibiotic-associated diarrhoea and <em>C. difficile</em> infectionsuggested that probiotics may reduce the risk of antibiotic-associated diarrhoea, but some results were not statistically significant. There weremixed findings onthe abilityof probiotics to prevent <em>C.difficile</em> associated diarrhoea, and the review found no studies reporting on the effectiveness of probiotics for treatment[<a class="bibliography-reference internal-reference" href="../../references/index.html">CADTH, 2018a</a>].</li></ul></li></ul><h5>Consider the possibility of a false-positive test result</h5><ul><li><em>C. difficile </em>may be an incidental finding in stools of people with diarrhoea due to another cause [<a class="bibliography-reference internal-reference" href="../../references/index.html">Starr, 2005</a>].Indiscriminate testingincreasesthe likelihood of a false positive result (examples of inappropriate testing in one study included people without diarrhoea and those who had recently used laxatives)[<a class="bibliography-reference internal-reference" href="../../references/index.html">Winslow et al, 2014</a>].<ul><li>Colonisation with<em>C. difficile</em>is quite common and people who are colonised may be asymptomatic[<a class="bibliography-reference internal-reference" href="../../references/index.html">Kazanowski et al, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Winslow et al, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Ong et al, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">McDonald et al, 2018</a>].</li></ul></li></ul><!-- end field dfcbfaee-f088-4010-9e5e-d3e3c72d5144 --><!-- end item 1e8a34b1-fff1-4ae0-b861-0ab03e377b8c --></div></section></section></section></div></div></div><div class="BackToTop-module--wrapper--2Z0EU"><nav aria-labelledby="back-to-top-link" class="BackToTop-module--nav--1DPZ6"><a class="BackToTop-module--anchor--1Nia6" id="back-to-top-link" href="index.html#content-start"><div class="container"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="icon" aria-hidden="true" focusable="false"><path d="M478.152 338.576c0 10.091-3.525 18.661-10.576 25.712l-21.424 21.424c-7.243 7.243-15.909 10.864-26 10.864-10.283 0-18.853-3.621-25.712-10.864L255.576 247.136 116.712 385.712c-6.859 7.243-15.429 10.864-25.712 10.864s-18.853-3.621-25.712-10.864l-21.424-21.424C36.621 357.429 33 348.859 33 338.576c0-10.091 3.621-18.757 10.864-26l186-186c7.051-7.051 15.621-10.576 25.712-10.576 9.909 0 18.576 3.525 26 10.576l185.712 186c7.243 7.243 10.864 15.909 10.864 26z" fill="currentColor"></path></svg> Back to top</div></a></nav></div></main><footer class="Footer-module--footer--2QrGZ"><div class="Footer-module--container--1iuoB"><a href="https://www.nice.org.uk/" class="Footer-module--logo--3DGKv" aria-label="Go to NICE home page"></a><nav class="Services-module--wrapper--2qOoE" aria-label="Our services"><ul class="Services-module--list--3SZQu"><li><a href="https://pathways.nice.org.uk/" class="Services-module--link--2y_1q">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Services-module--link--2y_1q">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Services-module--link--2y_1q">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Services-module--link--2y_1q">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary">BNF<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Services-module--link--2y_1q"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Services-module--visuallyHidden--t9mfm">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">Clinical Knowledge Summaries</span></a></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Services-module--link--2y_1q">Journals and databases</a></li></ul></nav><nav class="Pages-module--wrapper--30REl"><ul class="Pages-module--list--vvSk4"><li><a href="https://www.nice.org.uk/about">About NICE</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/into-practice">Into practice</a></li><li><a href="https://www.nice.org.uk/get-involved">Get involved with NICE</a></li><li><a href="https://www.nice.org.uk/get-involved/jobs">Jobs</a></li><li><a href="https://www.nice.org.uk/news">News</a></li><li><a href="https://www.nice.org.uk/news/nice-newsletters-and-alerts">Newsletters and alerts</a></li><li><a href="https://www.nice.org.uk/get-involved/contact-us">Contact us</a></li><li><a href="https://www.nice.org.uk/leave-feedback">Leave feedback</a></li><li><a href="https://www.nice.org.uk/re-using-our-content">Reusing our content</a></li><li><a href="https://www.nice.org.uk/re-using-our-content/uk-open-content-licence">NICE UK Open Content Licence</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/nice-syndication-api">Syndicate our content</a></li></ul></nav><div class="Social-module--wrapper--2nKsd"><ul class="Social-module--list--E5R5J" aria-label="NICE on social media"><li><a href="https://en-gb.facebook.com/NationalInstituteforHealthandCareExcellence/">Facebook</a></li><li><a href="https://twitter.com/NICEcomms">Twitter</a></li><li><a href="https://www.youtube.com/user/NICEmedia">YouTube</a></li><li><a href="https://www.instagram.com/nicecomms/">Instagram</a></li><li><a href="https://www.linkedin.com/company/national-institute-for-health-and-clinical-excellence">LinkedIn</a></li></ul></div></div><div class="Legal-module--wrapper--3AYMO"><div class="Legal-module--container--3TTBh"><nav class="Legal-module--menu--1e1Iy" aria-label="Legal menu"><ul><li><a href="https://www.nice.org.uk/accessibility">Accessibility</a></li><li><a href="https://www.nice.org.uk/freedom-of-information">Freedom of information</a></li><li><a href="https://www.nice.org.uk/glossary">Glossary</a></li><li><a href="https://www.nice.org.uk/terms-and-conditions">Terms and conditions</a></li><li><a href="https://www.nice.org.uk/privacy-notice">Privacy notice</a></li><li><a href="https://www.nice.org.uk/cookies">Cookies</a></li></ul></nav><p class="Legal-module--copyright--34nsI"><!-- --> <abbr title="National Institute for Health and Care Excellence">NICE</abbr> <!-- -->2021<!-- -->. All rights reserved. Subject to<!-- --> <a href="https://www.nice.org.uk/terms-and-conditions#notice-of-rights">Notice of rights</a>.</p></div></div></footer></div><div id="gatsby-announcer" style="position:absolute;top:0;width:1px;height:1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);white-space:nowrap;border:0" aria-live="assertive" aria-atomic="true"></div></div><script id="gatsby-script-loader">/*<![CDATA[*/window.pagePath="/topics/diarrhoea-antibiotic-associated/management/diarrhoea-antibiotic-associated/";/*]]>*/</script><script id="gatsby-chunk-mapping">/*<![CDATA[*/window.___chunkMapping={"polyfill":["/polyfill-2cb897c2a056d28c9332.js"],"app":["/app-53a71c38b210970893c4.js"],"component---cache-caches-gatsby-plugin-offline-app-shell-js":["/component---cache-caches-gatsby-plugin-offline-app-shell-js-258fa972005c75a2a109.js"],"component---src-pages-404-tsx":["/component---src-pages-404-tsx.4b20f8dadfa146d0f95d.css","/component---src-pages-404-tsx-db046304e34e9a4e982b.js"],"component---src-pages-about-development-tsx":["/component---src-pages-about-development-tsx.4c5b5dd941fb0f6fd929.css","/component---src-pages-about-development-tsx-a805dcaba6372bd3fd34.js"],"component---src-pages-about-index-tsx":["/component---src-pages-about-index-tsx.a9a4b7f951b698486005.css","/component---src-pages-about-index-tsx-d5e998d3f688352286e1.js"],"component---src-pages-index-tsx":["/component---src-pages-index-tsx.49dafffcf9ae0c5f0d9f.css","/component---src-pages-index-tsx-6cc2ff789de11ec327f6.js"],"component---src-pages-search-tsx":["/component---src-pages-search-tsx.f915457cd8b05c27e895.css","/component---src-pages-search-tsx-a51f99760cb0d47808e2.js"],"component---src-pages-specialities-tsx":["/component---src-pages-specialities-tsx.fc62cf637c7ba1e609e7.css","/component---src-pages-specialities-tsx-90b8d3e5a5a3bff52a17.js"],"component---src-pages-topics-tsx":["/component---src-pages-topics-tsx.dfa0c1027e3cbeb11bdc.css","/component---src-pages-topics-tsx-960f75c13acbee11c017.js"],"component---src-pages-whats-new-tsx":["/component---src-pages-whats-new-tsx.7f7660f22ce5e07ac85a.css","/component---src-pages-whats-new-tsx-f78b713a66b42005fd9f.js"],"component---src-templates-chapter-level-1-chapter-level-1-tsx":["/component---src-templates-chapter-level-1-chapter-level-1-tsx.1a16ce552cccd7e50c41.css","/component---src-templates-chapter-level-1-chapter-level-1-tsx-0a03778bb80ba711929e.js"],"component---src-templates-chapter-level-2-chapter-level-2-tsx":["/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css","/component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"],"component---src-templates-speciality-speciality-tsx":["/component---src-templates-speciality-speciality-tsx.fc62cf637c7ba1e609e7.css","/component---src-templates-speciality-speciality-tsx-3357943d471e489a1b5f.js"],"component---src-templates-topic-topic-tsx":["/component---src-templates-topic-topic-tsx.afc04214919e241c3c2e.css","/component---src-templates-topic-topic-tsx-f17fe03d0b9a54a96aea.js"]};/*]]>*/</script><script src="../../../../polyfill-2cb897c2a056d28c9332.js" nomodule=""></script><script src="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js" async=""></script><script src="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js" async=""></script><script src="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js" async=""></script><script src="../../../../app-53a71c38b210970893c4.js" async=""></script><script src="../../../../framework-34da02e39e1f104d9937.js" async=""></script><script src="../../../../webpack-runtime-28c424ef71f39faedaf0.js" async=""></script></body></html>